

Synthesis and Configurational Assignment of Vinyl Sulfoximines and Sulfonimidamides

Gregory B. Craven,* Edward L. Briggs, Charlotte M. Zammit, Alexander McDermott, Stephanie Greed, Dominic P. Affron, Charlotte Leinfellner, Hannah R. Cudmore, Ruth R. Tweedy, Renzo Luisi, James A. Bull,* and Alan Armstrong*



Cite This: *J. Org. Chem.* 2021, 86, 7403–7424



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Vinyl sulfones and sulfonamides are valued for their use as electrophilic warheads in covalent protein inhibitors. Conversely, the S(VI) aza-isosteres thereof, vinyl sulfoximines and sulfonimidamides, are far less studied and have yet to be applied to the field of protein bioconjugation. Herein, we report a range of different synthetic methodologies for constructing vinyl sulfoximine and vinyl sulfonimidamide architectures that allows access to new areas of electrophilic chemical space. We demonstrate how late-stage functionalization can be applied to these motifs to incorporate alkyne tags, generating fully functionalized probes for future chemical biology applications. Finally, we establish a workflow for determining the absolute configuration of enantioenriched vinyl sulfoximines and sulfonimidamides by comparing experimentally and computationally determined electronic circular dichroism spectra, enabling access to configurationally assigned enantiomeric pairs by separation.



INTRODUCTION

Sulfoximines and sulfonimidamides, the mono aza-analogues of sulfones and sulfonamides, respectively, are gaining traction as valuable pharmacophores in medicinal chemistry (Figure 1a).^{1,2} Architecturally, these motifs carry asymmetry at the tetrahedral sulfur center, offer hydrogen-bond acceptor and donor functionalities for NH derivatives, and afford new vectors along which to generate structural complexity. Bioactive sulfoximines date back to the discovery of methionine sulfoximine, which was later discovered to be a prodrug inhibitor of glutamine synthetase.³ More recently, new synthetic methodologies have facilitated the incorporation of sulfoximine and sulfonimidamide motifs into drug discovery programs, through which their high chemical and stereochemical stability as well as favorable physicochemical properties have been uncovered.⁴ Indeed, three sulfoximine compounds have entered clinical trials in recent years, with their desirable drug metabolism and pharmacokinetics (DMPK) profiles being cited as key triggers for candidate selection.⁵

Vinyl sulfones and sulfonamides are well-characterized electrophiles and have been extensively utilized as reactive warheads in protein-targeted covalent probes.⁶ For example, substituted vinyl sulfones are found in cysteine-targeting covalent cathepsin inhibitors,⁷ terminal vinyl sulfones have been used in lysine-targeting cyclin-dependent kinase 2 (Cdk2) inhibitors,⁸ and terminal vinyl sulfonamides have

been employed to target cysteine residues on a variety of proteins including mitogen-activated protein kinase 1 (ERK2),⁹ mutant KRas(G12C),¹⁰ Bruton's tyrosine kinase (BTK),¹¹ and ubiquitin-specific protease 7 (USP7)¹² (Figure 1b). Synthetic routes to these scaffolds are well established, and probe specificity is engineered by installation of pharmacophores that bind the target protein and orientate the electrophile to react with a nearby nucleophilic amino acid.¹³


We speculated that vinyl sulfoximines and sulfonimidamides could similarly act as protein reactive warheads in covalent probes.¹⁴ The value of these aza-analogues compared to the established vinyl S(VI) electrophiles would arise from their ability to offer alternative hydrogen-bonding architectures, additional vectors for pharmacophore incorporation, and likely different reactivity profiles. Moreover, the new nitrogen center offers a convenient handle for the attachment of chemical biology functionalities, such as alkynes and fluorophores, to generate fully functionalized probes.¹⁵ As these derivatives are chiral at sulfur, they present increased complexity and potential

Received: February 15, 2021

Published: May 18, 2021




(a) S(VI) aza-isosteres




(b) S(VI) Covalent Probes


Substituted vinyl sulfones



Terminal vinyl sulfones



Terminal vinyl sulfonamides



Vinyl sulfoximines/sulfonimidamides






Figure 1. (a) S(VI) aza-isosteres. (b) Examples of established vinyl sulfone- and sulfonamide-based covalent inhibitors and proposed scaffolds for future aza-analogues.

Scheme 1. Previous Routes to Vinyl Sulfoximines

Substituted *E*-vinyl sulfoximines via β -hydroxy elimination


Hwang (1987): imidation with $\text{NaN}_3/\text{H}_2\text{SO}_4$; elimination with CDI

Craig (1993): imidation with $\text{NaN}_3/\text{H}_2\text{SO}_4$; elimination with MeOCOCI

Substituted *E*-vinyl sulfoximines via HWE reaction

Hwang (2000): R = Ar; SiR'_3 = TMS; imidation with $\text{NaN}_3/\text{H}_2\text{SO}_4$

Bolm (2007): R = Me; SiR'_3 = TBDPS; imidation with $\text{NaN}_3/\text{H}_2\text{SO}_4$




Arvidsson (2016): PG-free; high-yielding; imidation with MSH

complementarity as probes. A recent work from Cravatt has demonstrated the value of using stereochemically paired fully functionalized probes in the context of proteomic screening, offering an internal control for nonspecific protein binding.¹⁶ More broadly, electrophilic fragments are now routinely screened to identify starting points for covalent probes, and

novel electrophilic functionalities are desirable to expand the diversity of covalent fragment libraries.^{17,18}

Over the last 30 years, β -substituted (*E*)-vinyl sulfoximines have been prepared by a variety of approaches utilizing carbonyl addition and then β -hydroxy activation/elimination,¹⁹ Peterson olefination,²⁰ and Horner–Wadsworth–Emmons

Scheme 2. Synthetic Methods Described in this Work to Access Vinyl Sulfoximines and Sulfonimidamides



(HWE) olefination²¹ (Scheme 1). More recently, Arvidsson reported an improved HWE sequence that is both high yielding and protecting group free.²² These methodologies demonstrate the chemical stability and tractability of the vinyl sulfoximine motif, and one such recent study has given rise to the first examples of bioactive vinyl sulfoximines that are thought to activate the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), although a covalent mechanism of action was not proposed.²³ However, these synthetic routes have clear limitations; they generally utilize multiple-step sequences that are reliant on the use of hydrazoic acid or *O*-(mesitylenesulfonyl)hydroxylamine (MSH) for sulfoxide imidation, both of which are known for their thermal instability.^{24,25} There are very few examples of terminal vinyl sulfoximines or enantioenriched vinyl sulfoximines. Moreover, the first two examples of vinyl sulfonimidamides were only reported very recently,²⁶ despite the prevalence of the analogous vinyl sulfonamides, which we attribute to the historically limited synthetic methodology regarding sulfonimidamides.


It is notable that in recent years the methods for sulfoximine and sulfonimidamide syntheses have developed considerably.^{27–29} In our groups, we have developed a safe and effective method for the NH transfer to sulfoxides to form sulfoximines using ammonium carbamate and (diacetoxy)-iodobenzene.³⁰ Similarly, we and others have developed a one-pot oxidation and imidation protocol for the direct conversion of sulfides to sulfoximines.^{31,32} Stockman and Lücking established a related process for the preparation of sulfonimidamides from sulfenamides.³³ We have developed the synthesis of sulfonimidamides from sulfenamides by NH and O transfer.³⁴ It is notable that using this NH-transfer methodology, the reaction of phenylvinylsulfoxide was effective in generating phenylvinyl sulfoximine, although in moderate yield (54%).³⁰ However, the corresponding method from the sulfide was ineffective (14% yield for phenylvinyl sulfide),^{31a}

presumably due to the instability of terminal vinyl sulfides to acid. Improved methods that expand the diversity of accessible products, minimize the use of dangerous reagents and enable the synthesis of fully functionalized probes for future chemical biology investigations would be of considerable interest.

Here, we report the development of new and improved synthetic routes for the preparation of vinyl sulfoximines, exploiting recent developments in the synthesis of aza-S(VI) derivatives. Three orthogonal routes to access terminal and substituted vinyl NH-sulfoximines are investigated, including highly enantioenriched examples (Scheme 2). Furthermore, we report some of the first examples of vinyl NH-sulfonimidamides. These studies considerably extend the scope of the hypervalent iodine-mediated NH-transfer methods and provide a comparison of available routes, highlighting strategies for different substitution patterns. A simple propargylation reaction to convert these products into fully functionalized probes is demonstrated. Finally, we generate stereochemically paired vinyl sulfoximine and sulfonimidamide derivatives, by late-stage chiral separation, and establish a method for their configurational assignment by combining density-functional theory (DFT) calculations and circular dichroism (CD). These approaches allow access to a range of stereochemically defined structures of interest as probes.

RESULTS AND DISCUSSION


Substituted Vinyl (*E*)-Sulfoximines from Methyl Sulfides and Sulfoxides. Our initial investigations focused on the established HWE approach to vinyl sulfoximine synthesis but commencing from simple sulfides and applying recent methods for NH transfer, using (diacetoxy)iodobenzene and ammonium carbamate, to improve the efficiency and safety.^{31a} Accordingly, methyl sulfides **1a** and **1b** were converted into the corresponding NH-sulfoximines **2a** and **2b** in very good yields (Scheme 3a). After *tert*-butyldiphenylsilyl (TBDPS) protection of the sulfoximine nitrogen to

Scheme 3. Synthesis of Substituted (*E*)-Vinyl Sulfoximines from (a) Methyl Sulfides and (b) Enantioenriched Methyl Sulfoxides

give intermediates **3a** and **3b**, a one-pot HWE procedure was implemented using a range of aldehyde coupling partners to furnish NTBDPS-protected vinyl sulfoximines **4a–g**. Finally, TBDPS deprotection with tetra-*n*-butylammonium fluoride (TBAF) afforded vinyl NH-sulfoximines **5a–g**. Both aromatic and aliphatic aldehydes gave similarly high yields for the two steps (**5a** and **5b**). Incorporation of an alkyne functionality was well tolerated (**5c** and **5e**), which is encouraging for the potential to generate future fully functionalized probes. The method also performed well using the more electron-rich

anisole-derived sulfoximine (**5e–g**) and using heteroaromatic aldehydes (**5d**, **5f**, **5g**).

Stereochemically enriched sulfoximines are finding increasing utility in drug discovery and asymmetric synthesis but represent synthetically challenging targets.^{4,5,35} Application of an analogous synthetic sequence to enantioenriched sulfoxides (**S**)-**6** and (**R**)-**6** using 4-ethynylbenzaldehyde furnished products (**S**)-**5h** and (**R**)-**5h**, respectively, with retention of the configuration at sulfur and without loss of enantiomeric excess (ee) (**Scheme 3b**).³⁰ The stereospecificity of this route and configurational stability of the intermediates and products

Scheme 4. Synthesis of Substituted (*E*)-Vinyl Sulfoximines via Alkyne Hydrothiolation

^aUsed 10 mol % $\text{RhCl}(\text{PPh}_3)_3$, 65 °C. ^b**9f** is exemplified in ref 13 using similar conditions.

Table 1. Synthesis of Terminal Vinyl Sulfoximines via Alcohol Elimination

Reaction scheme showing the synthesis of terminal vinyl sulfoximines (**13a-d** and **14a-d**) from sulfide (**11a-d**) via alcohol elimination to form sulfoximine (**12a-d**), followed by conversion to vinyl sulfoximine (**13a-d** or **14a-d**) using MsCl (1.05 equiv) and NEt_3 (4 equiv) in CH_2Cl_2 , 0 to 25 °C.


Sulfide 11	Yield		
	Sulfoximine 12 (i)	NH vinyl sulfoximine 13 (ii)	NMs vinyl sulfoximine 14 (ii)
	a 73%	50%	6%
	b 87%	52%	-
	c 54%	39%	-
	d 91%	35%	29%

are encouraging for the design of future stereochemically defined vinyl sulfoximines. Indeed, powerful methods are well established for the enantioselective oxidation of unsymmetrical methyl sulfides,³⁶ which could be combined with this HWE route to provide access to a broad range of enantioenriched vinyl sulfoximines. By incorporating alkyne functionalities into (*S*)-**5h** and (*R*)-**5h**, these structures represent the first example of stereochemically paired fully functionalized vinyl sulfoximine probes.

Substituted (*E*)-Vinyl Sulfoximines via Alkyne Hydrothiolation. Next, we sought to develop a more efficient route to vinyl sulfoximines to expand the product scope and notably avoid the use of protecting groups and possible regiochemical ambiguity in the deprotonation step of dialkyl sulfoximines.

We anticipated that direct oxidation/imidation of vinyl thioethers would be the most direct path. A range of metal-catalyzed alkyne hydrothiolation reactions have been developed that facilitate the synthesis of branched,^{37,38} linear (*E*)-vinyl thioethers,³⁹ or linear (*Z*)-vinyl thioethers⁴⁰ in high selectivity. For this study, we were interested in linear (*E*)-vinyl sulfoximines and applied a Wilkinson's catalyst-mediated alkyne thiolalkylation methodology reported by Love, which gives high levels of stereocontrol using 1,2-dichloroethane (DCE) as the solvent.⁴¹ The (*E*)-vinyl thioether products **9** were then converted to the corresponding (*E*)-vinyl sulfoximines **10** using our NH/O-transfer method (Scheme 4).^{31a} This two-step sequence provided efficient access to a diverse range of vinyl sulfoximines in good to excellent yields,

Scheme 5. Synthesis of Terminal Vinyl Sulfonylamides via Alcohol Elimination



tolerating silyl (**10a**, **10b**), aryl (**10c–e**), and alkyl (**10f**) alkynes in combination with aryl (**10a**, **10c**, **10d**, and **10f**) and alkyl (**10b** and **10e**) thiols. The success of this methodology for alkyl thiols is particularly exciting since access to such products by HWE chemistry is challenging. Indeed, the incorporation of an aryl bromide containing alkyne (**10e**) and thiol (**10d**) will enable elaboration of these scaffolds in multiple vectors using transition-metal-catalyzed coupling chemistry. Pleasingly, we were also able to remove the Boc protection group from **10f** to afford amine **10g**, offering a useful handle for functionalization at the amine.

Terminal Vinyl Sulfoximines via Alcohol Elimination.

An alternative synthetic approach was needed to access terminal vinyl sulfoximines. We implemented a two-step sequence based on the controlled activation and elimination of β -hydroxyethyl sulfoximines (Table 1). β -Hydroxy thioethers **11a–d** were converted to the corresponding sulfoximines **12a–d** in fair-to-excellent yields. Treating alcohols **12a–d** with a slight excess of methanesulfonyl chloride and base led to activation and elimination of the alcohol to give the desired NH vinyl sulfoximines **13a–d**. The methodology is suitable for producing aromatic (**13a** and **13b**), heteroaromatic (**13c**), and alkyl (**13d**) vinyl sulfoximines. The mesylation step generally proceeded with good *O/N* chemoselectivity; however, we were additionally able to isolate the *N*-mesyl vinyl sulfoximines in some cases (**14a** and **14d**) as side products. We anticipate that the *N*-mesyl vinyl sulfoximines would be more electrophilic and reactive than the NH analogues and may represent an interesting new class of electrophile in their own right.


Terminal Vinyl Sulfonylamides via Alcohol Elimination. We envisioned that an analogous β -hydroxyethyl activation/elimination strategy could be implemented to generate vinyl sulfonylamides by combining it with our sulfenamide oxidation/imidation method.³³ Accordingly, phenyl piperidine (**15a**) was treated with tetrahydropyranyl (THP)-protected β -hydroxyethyl disulfide (**16**) and silver nitrate to generate the corresponding sulfenamide (Scheme 5). The inclusion of Et₃N, in modified conditions, gave improved results by reducing the acidity of the reaction. The sulfenamide was then simultaneously imidated and oxidized using

ammonium carbamate and iodosylbenzene to give the THP-protected β -hydroxy sulfonylamide **17a** in 57% yield over two steps. After THP deprotection, mesylation and in situ elimination afforded the desired vinyl sulfonylamide **18a** in 46% over two steps. Notably, the mesylation reaction proceeded with excellent *O/N* chemoselectivity for the alcohol over the sulfonylamide. This novel class of electrophile was stable toward silica gel chromatography and showed no noticeable degradation when stored at –20 °C in dimethyl sulfoxide (DMSO) over 6 months. To further exemplify the methodology, we synthesized three additional vinyl sulfonylamides **18b–d**. Starting with racemic 1-methyl-3-phenylpiperazine **16b** gave vinyl sulfonylamide **18b** (diastereomer ratio (dr) 1:2). Encouragingly, the reaction sequence was successful with nortriptyline **15c**, demonstrating that bioactive motifs can also be converted into vinyl sulfonylamides. This route has delivered some of the first examples of a chemical motif that has significant potential for future probe design.

N-Propargylation of Vinyl Sulfoximines and Sulfonylamides. The incorporation of alkyne tags onto small molecules is a highly valuable transformation that enables chemical biology experiments such as activity-based protein profiling and fluorescence microscopy.⁴² In the context of covalent protein targeting probes, the addition of an alkyne tag generates a fully functionalized probe that facilitates visualization and quantification of target engagement.¹⁵ The majority of the previously established covalent warheads do not possess convenient chemical handles for attachment of alkyne tags.^{14b} As such, the design of fully functionalized probes often requires preinstallation of the alkyne handle into the pharmacophore, which can be synthetically challenging.⁴³ Therefore, a general method for late-stage propargylation of small molecules would present significant benefits and opportunities to chemical biologists.

Functionalization, including propargylation, of sulfoximine-NH groups has been widely reported, though for sulfonylamides much less so.^{44–46} Vinyl sulfoximines and sulfonylamides are electrophilic in nature, which raises potential reaction compatibility concerns. Pleasingly, however, a diverse range of vinyl sulfoximines and sulfonylamides could be efficiently propargylated using sodium hydride and propargyl

Scheme 6. N-Propargylation of Vinyl Sulfoximines and Sulfonimidamides



bromide (Scheme 6). Terminal (19a), substituted (19b and 19c), and heteroaromatic (19d) vinyl sulfoximines as well as tertiary amines-containing vinyl sulfonimidamides (19e, 19f) and bioactive-pharmacophore containing vinyl sulfonimidamide (19g) were all well tolerated.

Configurational Assignment of Enantioenriched Vinyl Sulfoximines and Sulfonimidamides. The binding between proteins and chemical probes often exhibits discriminatory affinity for different stereoisomers. Indeed, the clinical candidate sulfoximine inhibitors roniciclib, atueviclib, and ceralasertib are all enantiopure.⁵ Therefore, the development of future probes relies on both access to enantioenriched vinyl sulfoximines and sulfonimidamides and the ability to assign their absolute configuration. Through the HWE reaction sequence, highly enantioenriched vinyl sulfoximines (*S*)-5h and (*R*)-5h (Scheme 3b) were prepared with a synthetically defined configuration. However, the other synthetic routes to vinyl sulfoximines and sulfonimidamides described herein generate racemic products with respect to the chiral sulfur center. Chiral separation, typically conducted by high-performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC), offers an alternative method for accessing enantioenriched products and has been highly successful with regard to the production of enantiopure sulfoxide drugs.^{47,48} The value of such separation is dependent on the reliable assignment of absolute configuration, which is typically accomplished by X-ray crystallography,⁴⁹ NMR,⁵⁰ or computational and experimental circular dichroism.⁵¹ Electronic circular dichroism (ECD) is among the most versatile of these techniques and has previously been successfully applied to the stereochemical assignment of sulfoxide drugs and sulfonimidamides.^{52–54} To establish whether ECD could be reliably applied to the configurational assignment of vinyl sulfoximines and sulfonimidamides, we first investigated whether quantum mechanical calculations could predict the experimentally observed ECD spectrum for (*R*)-5h with high confidence.

A conformational search (see the Supporting Information) was performed on the vinyl sulfoximine unit using the B3LYP

functional and the 6-31G* basis set. The low-energy conformers (within 3 kcal/mol of the lowest) were further optimized using cam-B3LYP/6-311++g(d,p) in a conductor-like polarizable continuum model (CPCM) of acetonitrile. We identified four minimum energy conformers of (*R*)-5h that are significantly populated at ambient temperature (Figure 2a). In the two lowest energy conformers (3 and 1), the vinyl group eclipses the S=O bond, with the two structures varying in the orientation of the NH group. Conformers 15 and 13, which are slightly higher in energy, have the vinyl group eclipsing the S=N bond. The electronic transitions of each conformer of (*R*)-5h were then calculated, and the UV-vis and ECD spectra were simulated and summed according to their Boltzmann weighting (Figure 2b). It should be noted that the calculated ECD spectra of conformers 3 and 1 were similar to each other in the experimental range (190–340 nm), while the calculated spectra of conformers 13 and 15 were also similar to each other, but with the significant peaks being opposite in sign to those of 3/1. The weighted ECD spectrum is therefore sensitive to the relative conformer energies at the vinyl-S=O dihedral. We then measured the ECD and UV-vis spectra of (*R*)-5h in acetonitrile experimentally and compared them to the calculated spectra using SpecDis, a dedicated software package for comparing ECD/UV spectral similarity.⁵⁵ Aligning the UV-vis spectra required a 11 nm positive shift correction factor of the calculated spectrum, giving good spectral matches that are characterized by a sharp peak at 197 nm and a broad peak between 270 and 320 nm. Applying the same 11 nm correction factor to the calculated ECD spectrum gave excellent correlation with the experimental ECD, defined by a trough between 200 and 217 nm, a double peak between 217 and 256 nm, and a second trough between 256 and 316 nm. To quantify the ECD spectral match, we applied similarity factor analysis, which gave an 80.7% match for the experimental (*R*)-5h ECD spectrum with the calculated (*R*)-5h spectrum but only a 0.7% match with the calculated (*S*)-5h spectrum. The resulting δ score of 80.0% represents a high confidence assignment and validates that this workflow is reliable and should be suitable for assigning the configuration




Figure 2. (a) Molecular modeling of the low-energy conformations of (*R*)-**5h**. (b) Comparison of calculated and experimental UV-vis and ECD spectra for (*R*)-**5h**.

of vinyl sulfoximines and sulfonimidamides with unknown stereochemistry.

Next, we selected three compounds **10g**, **19g**, and **19f** for chiral separation, which was performed using the automated HPLC/SFC condition screening system at Reach Separations,⁵⁶ and de novo configurational assignment by ECD using the same modeling workflow and parameters as described for (*R*)-**5h** (Table 2). Chiral separation of **10g**, where the carbon stereocenter is synthetically defined as (*S*), gave two diastereoisomers **10g-A** and **10g-B** as neutral amines. ECD calculation for **10g** is challenging because of the presence of the second stereocenter and the conformational flexibility of the acyclic allylic amine. We examined two approaches to simplify this problem. In the first, we used a single fixed, low-energy conformation of the vinyl amine portion appended to the four conformers of the allylic sulfoximine unit found for **5h**. We modeled both (*R,S*)-**10g** and (*S,S*)-**10g** in this way (Figure S1). The (*R,S*)-**10g** and (*S,S*)-**10g** models gave distinct calculated ECD spectra, and comparison with the experimental spectra gave the best match for **10g-A** = (*R,S*)-**10g** and **10g-B** = (*S,S*)-**10g**, with a mean similarity score of 78.6% (Figure S2). This assignment is made with high confidence given that the mean similarity score for the opposite assignment is only 37.1%. To simplify the modeling further for future applications, we also modeled a phenylvinyl sulfoximine substructure of **10g** that lacks the chiral amine functionality. We found that comparing the predicted ECD spectrum of substructure-**10g** with the experimental racemic-subtracted ECD spectrum of **10g** gave the same assignment as modeling the full structure with a similar confidence level (δ score = 80.6%) (Figure S3).

Vinyl sulfonimidamide **19g** was separated into its two enantiomers **19g-A** and **19g-B**, which were isolated in very high enantiomeric purity. The biaryl system is achiral and was anticipated not to make a significant contribution to the ECD spectrum, while the flexible nature of the alkyl linker would make the conformational modeling challenging. Accordingly, we modeled (*R*)-**20** as the key substructure, which yielded three low-energy conformers. In analogy with vinyl sulfoximine **5h** and **10g**, the two lower-energy conformers (differing by 0.17 kcal mol⁻¹) have the vinyl group eclipsing the S=O bond, with the two structures varying in the orientation of the *N*-propargyl group, while for the higher-energy conformer (+0.75 kcal mol⁻¹), the vinyl group eclipses the S=N bond (Figure S4). Comparing the calculated and experimental UV-vis and ECD spectra led to an unambiguous assignment of **19g-A** = (*R*) and **19g-B** = (*S*) configurations with a high confidence (δ score = 91.5%) (Figure S5).









Chiral separation of **19f** gave four stereoisomers **19f-A–D** that were each isolated in high levels of stereo purity. By comparing the NMR spectra of each isomer, **19f-A** and **19f-D** were assigned as one enantiomeric pair and **19f-B** and **19f-C** as the other, although no information about their relative configuration could be obtained. We then modeled both (*R,S*)-**19f** and (*S,S*)-**19f**, which gave four and five low-energy (≤ 1.5 kcal mol⁻¹) conformers, respectively, with the piperazine ring adopting a chairlike conformation and the phenyl ring pointing axially in each case (Figure S6). Conformers in which the phenyl ring points equatorially were substantially higher in energy (≥ 2.2 kcal mol⁻¹) for both (*R,S*)-**19f** and (*S,S*)-**19f** and made little-to-no contribution to the calculated ECD. Of note, while for (*R,S*)-**19f** the two lowest energy conformers have the vinyl group eclipsing S=O, for (*S,S*)-**19f** the lowest four conformers are of very similar energy, two of them having the vinyl group eclipsing S=N, and two having it eclipse S=O. Determining the configuration of diastereoisomers by ECD is typically challenging because they often have closely related ECD spectral profiles. However, in this case, the calculated Boltzmann-weighted ECD spectra of all four stereoisomers gave strikingly different shapes. Comparing the UV and ECD spectra of each isomer with the modeled spectra, we found that **19f-A** has a nearly exact match (98.9%) with (*R,S*)-**19f** and **19f-B** gave an excellent match (97.4%) with (*S,S*)-**19f**, allowing us to make a high confidence assignment of all four isomers (Figure S7).


CONCLUSIONS

Vinyl sulfoximines and sulfonimidamides offer significant potential as functionalizable electrophilic warheads but have seen little exploration to date. We have developed several new synthetic approaches to these motifs that expand the potential of these motifs and access a much wider range of derivatives. First, we showcased a modified HWE sequence, from methyl sulfides, providing NH vinyl sulfoximines exclusively as the *E*-isomers. Application of this HWE sequence to enantioenriched methyl sulfoxides gave an efficient route to enantioenriched vinyl sulfoximines. Next, we developed a two-step route to vinyl sulfoximines that exploits alkyne hydrothiolation and a highly chemoselective one-pot transfer of NH and O to vinyl sulfides. This route is substantially shorter than previous approaches and works well for both alkyl and aryl vinyl sulfoximines.

Terminal vinyl sulfoximine and sulfonimidamides represent particularly challenging synthetic targets that could have

Table 2. Chiral Separation and Configurational Assignment of Vinyl Sulfoximine and Sulfonimidamides Stereoisomers by Molecular Modeling and ECD

Compound	HPLC purification	Modeled structure/substructure	ECD similarity score	Assignment
 10g	Chiralpak IG (MeOH + 0.2% NH ₃) Isomer 10g-A 99% de (rt = 3.7 min) Isomer 10g-B 97% de (rt = 4.5 min)	 (R,S)-10g	10g-A = 87.1% 10g-B = 58.8%	10g-A = (R,S)- 10g 10g-B = (S,S)- 10g Mean similarity score 78.6%
		 (S,S)-10g	10g-A = 15.3% 10g-B = 70.0%	
 19g	Chiralpak IG (50:50 heptane:IPA) Isomer 19g-A 99% ee (rt = 3.8 min) Isomer 19g-B 98% ee (rt = 4.9 min)	 (R)-20	19g-A = 91.7% 19g-B = 0.3%	19g-A = (R)- 19g 19g-B = (S)- 19g Delta score 91.5%
 19f Enantiomeric pairs determined by NMR: Pair 1 = 19f-A & 19f-D Pair 2 = 19f-B & 19f-C	Amylose-C (90:10 heptane:EtOH) Isomer 19f-A 100% ee, 100% de (rt = 4.3 min) Isomer 19f-B 100% ee, 100% de (rt = 5.8 min) Isomer 19f-C 96% ee, 100% de (rt = 7.2 min) Isomer 19f-D 100% ee, 97% de (rt = 8.4 min)	 (R,S)-19f	19f-A = 98.9% 19f-B = 28.1% 19f-C = 62.8% 19f-D = 0.1%	19f-A = (R,S)- 19f 19f-B = (S,S)- 19f 19f-C = (R,R)- 19f 19f-D = (S,R)- 19f Mean similarity score 98.2%
		 (S,S)-19f	19f-A = 11.7% 19f-B = 97.4% 19f-C = 1.9% 19f-D = 86.7%	



widespread application as warheads in covalent probes. We developed a simple two-step route to terminal vinyl sulfoximines from β -hydroxyethyl thioethers involving sulfoximine formation and alcohol activation/elimination. This approach is also extended to terminal vinyl sulfonimidamides, about which very little is known. Both vinyl sulfoximines and sulfonimidamides can be readily *N*-functionalized with an alkyne tag. These products have the potential to be utilized as fully functionalized probes in a range of chemical biology applications.

Finally, we developed a computational workflow for assigning the configuration of vinyl sulfoximines and sulfonimidamides using ECD. After validating the approach against a vinyl sulfoxide with a synthetically defined and known configuration, we apply the approach to the de novo assignment of enantiomeric and diastereoisomeric vinyl sulfoximines and vinyl sulfonimidamides. This methodology enables the implementation of chiral separation techniques to be applied to separate racemic vinyl sulfoximines and sulfonimidamides and assign their configuration, giving access to a range of new enantioenriched products.

Taken together, the methods we have exemplified in this work provide the tools to access new areas of electrophilic chemical space. Our investigations into the application of vinyl sulfoximines and sulfonimidamides to chemical biology are currently underway.

EXPERIMENTAL SECTION

General Experimental Considerations. All nonaqueous reactions were carried out under an inert atmosphere (argon) with flame-

dried glassware, using standard techniques. Anhydrous solvents were obtained by filtration through drying columns (tetrahydrofuran (THF), CH₂Cl₂, toluene). Forward-phase flash column chromatography was performed on an Isolera Spektra flash purification system using Biotage SNAP KP-Sil flash purification cartridges or SNAP Ultra flash purification cartridges, with the indicated solvent gradient. Reversed-phase flash column chromatography was performed using Biotage SNAP Ultra C18 cartridges. Analytical thin-layer chromatography (TLC) was performed on precoated aluminum-backed silica gel plates. Visualization of the developed chromatogram was performed by UV absorbance (254 nm) and/or stained with aqueous potassium permanganate solution, aqueous ceric ammonium molybdate, or a ninhydrin solution in ethanol. Nuclear magnetic resonance spectra were recorded on a 400 MHz spectrometer. Chemical shifts for ¹H NMR spectra are recorded in parts per million (ppm) from tetramethylsilane with the residual protic solvent resonance as the internal standard (chloroform: δ 7.27 ppm, methanol: δ 3.31 ppm). Data are reported as follows: chemical shift (multiplicity [s, singlet; d, doublet; t, triplet; m, multiple; and br, broad], coupling constant (in hertz), integration). ¹³C NMR spectra are recorded with complete proton decoupling. Chemical shifts are reported in parts per million from tetramethylsilane with the solvent resonance as the internal standard (¹³CDCl₃: δ 77.0 ppm, ¹³CD₃OD: δ 49.0 ppm). ¹⁹F NMR spectra were recorded with complete proton decoupling. Chemical shifts are reported in parts per million, referenced to fluorobenzene as a standard at δ -113.5 ppm. Commercial reagents were used as supplied or purified by standard techniques where necessary. Optical rotations (α) were recorded at the indicated temperature (*T* °C) and were converted to the corresponding specific rotations [α]_D^T.

General Procedure A: Preparation of NH-Sulfoximines from Sulfides by One-Pot *N*- and *O*-Transfer. The procedure was adapted from Tota et al.^{31a} Sulfide (4.8 mmol, 1.0 equiv), (diacetoxyiodo)-benzene (12.0 mmol, 2.5 equiv), and ammonium carbamate (9.6

mmol, 2.0 equiv) were added to a flask containing a stirrer bar. MeOH (0.5 M) was added, and the reaction was stirred at 25 °C for 3 h. The solvent was removed under reduced pressure. Purification by flash chromatography afforded the sulfoximine product.

General Procedure B: TBDPS Protection of Sulfoximine. A solution of imidazole (5.2 mmol, 2.0 equiv) in anhydrous dimethylformamide (DMF) was added to sulfoximine (2.6 mmol, 1.0 equiv). The reaction mixture was cooled to 0 °C, and *tert*-butyldiphenylsilyl chloride (3.3 mmol, 1.25 equiv) was added dropwise to the mixture. The solution was heated to 60 °C using a heating block and stirred for 64 h under nitrogen, after which the reaction was quenched with water (10 mL). The aqueous layer was extracted with CH₂Cl₂ (3 × 20 mL), and the organic extracts were washed with water (10 mL) and brine (10 mL). The combined organic extracts were then dried (MgSO₄), filtered, and concentrated in vacuo. Purification by flash chromatography afforded the TBDPS protected sulfoximine product.

General Procedure C: Preparation of Vinyl Sulfoximines by a Horner–Wadsworth–Emmons Reaction. *n*BuLi (1.35 mmol, 1.3 M in hexane, 2.7 equiv) was added to a solution of diisopropylamine (0.75 mmol, 1.5 equiv) in anhydrous THF at –78 °C under nitrogen. The resulting solution was warmed to room temperature over 30 min, before being cooled to –78 °C again. The TBDPS protected sulfoximine (0.50 mmol, 1.0 equiv) in anhydrous THF was added dropwise to the reaction mixture and stirred at –78 °C for a further 1 h. Diethylchlorophosphate (0.65 mmol, 1.3 equiv) was added dropwise. After 5 min, *t*BuOK (0.65 mmol, 1.0 M in THF, 1.3 equiv) was added and the mixture was stirred for 10 min after which a solution of aldehyde (1.00 mmol, 2.0 equiv) in anhydrous THF was added. The solution was then allowed to warm to 0 °C and stirred for 2 h. The reaction was quenched with 5% w/w aq. H₃PO₄ (10 mL). The aqueous layer was extracted with Et₂O (3 × 20 mL), and the organic extracts were washed with 5% w/w aq. H₃PO₄ (2 × 20 mL). The combined organic extracts were then dried (MgSO₄), filtered, and concentrated in vacuo. Purification by flash chromatography afforded the TBDPS protected vinyl sulfoximine product.

General Procedure D: TBDPS Deprotection of Vinyl Sulfoximines. TBAF (0.29 mmol, 1.0 M in THF, 1.1 equiv) was added dropwise to a solution of TBDPS protected vinyl sulfoximine (0.26 mmol, 1.0 equiv) dissolved in anhydrous THF under nitrogen at room temperature. The reaction mixture was monitored by TLC every hour until the reaction was complete. The reaction mixture was flushed through a silica plug with Et₂O and concentrated in vacuo. Purification by flash chromatography afforded the NH vinyl sulfoximine product.

General Procedure E: Preparation of NH-Sulfoximines from Sulfoxides by One-Pot N-Transfer. The procedure was adapted from Zenzola et al.³⁰ Sulfide (1.62 mmol, 1.0 equiv), (diacetoxyiodo)benzene (4.86 mmol, 3.0 equiv), and ammonium carbamate (6.48 mmol, 4.0 equiv) were added to a flask containing a stirrer bar. MeOH (0.5 M) was added, and the reaction was stirred at 25 °C for 3 h. The solvent was removed under reduced pressure. Purification by flash chromatography afforded the sulfoximine product.

General Procedure F: Alkyne Hydrothiolation. The procedure was adapted from Shoai et al.⁴¹ RhCl(PPh₃)₃ (0.05 mmol, 5 mol %) and any other solid reagents (thiol (1.1 mmol, 1.1 equiv)/alkyne (1.0 mmol, 1.0 equiv)) were added to a microwave vial and sealed. The flask was evacuated and filled with N₂ three times before adding any liquid reagents (thiol (1.1 mmol, 1.1 equiv)/alkyne (1.0 mmol, 1.0 equiv)) and 1,2-dichloroethane (0.1 M) at 25 °C. The flask was left to stir for 18 h before the solvent was removed under reduced pressure. Purification by flash column chromatography afforded the corresponding vinyl sulfide product.

General Procedure G: Terminal Vinyl Sulfoximine Synthesis by Alcohol Mesylation and In Situ Elimination. Mesyl chloride (0.80 mmol, 1 M in CH₂Cl₂, 1.05 equiv) was added dropwise to a stirred solution of triethylamine (3.04 mmol, 4.0 equiv) and alcohol (0.76 mmol, 1.0 equiv) in CH₂Cl₂ (0.1 M) at 0 °C and left to warm to room temperature. After 1 h, the solvent was removed under reduced pressure. Purification by flash column chromatography afforded the

corresponding vinyl NH sulfoximine and in some cases N-mesylated vinyl sulfoximine products.

General Procedure H: Synthesis of Sulfonimidamides from Amines via a Sulfenamide Intermediate. The procedure was adapted from Briggs et al.³⁴ Amine (3.33 mmol, 1.33 equiv), triethylamine (2.0–3.5 equiv), and silver nitrate (5.0 mmol, 2.0 equiv) were added to a stirred solution of disulfide **16** (2.5 mmol, 1.0 equiv) in MeOH (0.1 M) at 25 °C, under air, for 1 h. The reaction mixture was filtered and washed with MeOH (2 × 50 mL). The filtrate solvent was removed under reduced pressure. H₂O (75 mL) was added to the crude mixture, and the aqueous mixture was extracted with Et₂O (3 × 75 mL). The combined organic layers were dried (Na₂SO₄) and filtered, and the solvent was removed under reduced pressure. Purification by filtration through a basic alumina (activity IV) plug (2 cm thick) afforded the corresponding crude sulfenamide intermediate. Iodosylbenzene (6.25 mmol, 2.5 equiv) and ammonium carbamate (5.0 mmol, 2.0 equiv) were added to the crude sulfenamide (2.5 mmol, 1.0 equiv) in a flask containing a stirrer bar under an argon atmosphere. A solution of acetic acid (0.2 M solution, corresponding to 1.0 equiv of AcOH) in *i*PrOH (0.2 M) was added, and the reaction was stirred for 1 h. The solvent was then removed under reduced pressure, and to the crude, sat. aq. NaHCO₃ was added (20 mL). The aqueous mixture was then extracted with CH₂Cl₂ (3 × 20 mL), and the combined organic layers were dried (Na₂SO₄) and filtered and the solvent was removed under reduced pressure. Purification by flash chromatography afforded the corresponding sulfonimidamide products.

General Procedure I: Vinyl Sulfonimidamides Synthesis by THP Deprotection and Alcohol Elimination. HCl (37% in H₂O, 1 mL) was added to a stirred solution of sulfonimidamide (0.65 mmol, 1 equiv) in MeOH/THF (1:1, 12 mL) at 25 °C. After 30 min, sat. aq. NaHCO₃ was added (25 mL). The aqueous mixture was then extracted with EtOAc (3 × 50 mL), the combined organic layers were dried (Na₂SO₄) and filtered, and the solvent was removed in vacuo to afford the crude alcohol intermediate. A solution of MsCl (0.68 mmol, 1 M in CH₂Cl₂, 1.05 equiv) was added dropwise to a solution of the crude alcohol (0.65 mmol, 1.0 equiv) and triethylamine (4.0 equiv) in CH₂Cl₂ (0.1 M) at 0 °C and left to warm to room temperature for 16 h. The solvent was removed in vacuo, and purification by flash chromatography afforded the corresponding vinyl sulfonimidamide products.

General Procedure J: N-Propargylation of Vinyl Sulfoximines and Sulfonimidamides. NaH (0.19 mmol, 60% in mineral oil, 1.2 equiv) was added to a solution of the sulfonimidamide (0.16 mmol, 1.0 equiv) in DMF (0.1 M) at 0 °C, and the reaction was stirred for 30 min. Propargyl bromide (0.22 mmol, 80% in toluene 1.5 equiv) was added, and the reaction was allowed to warm to room temperature for 3 h. H₂O (10 mL) was added, and the aqueous mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried (Na₂SO₄) and filtered, and the solvent was removed in vacuo. Purification flash chromatography afforded the corresponding N-propargyl sulfoximine or sulfonimidamide products.

Substituted Vinyl Sulfoximines 5a–g. Imino(methyl)(phenyl)-λ⁶-sulfanone (2a). The title compound was prepared according to General Procedure A employing diacetoxyiodobenzene (3.90 g, 12.1 mmol), ammonium carbamate (753 mg, 9.66 mmol), and thioanisole (600 mg, 4.83 mmol) in MeOH (9.6 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, product eluted at 100%) afforded **2a** as a yellow oil (644 mg, 86%); *R*_f = 0.42 (100% EtOAc); ¹H NMR (400 MHz, CDCl₃) δ 7.97–7.95 (m, 2H), 7.58–7.55 (m, 1H), 7.51–7.48 (m, 1H), 3.06 (s, 3H), 2.02 (s, 1H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 143.4, 133.1, 129.3 (2 × C), 127.7 (2 × C), 46.0; high-resolution mass spectrometry (HRMS) (electrospray ionization-time-of-flight (ESI-TOF)) *m/z*: calcd C₇H₁₀NOS⁺ [M + H]⁺, 156.0478; found, 156.0482. Analytical data are in agreement with those reported in the literature.³³

Imino(4-methoxyphenyl)(methyl)-λ⁶-sulfanone (**2b**)

The title compound was prepared according to General Procedure A employing diacetoxyiodobenzene (10.4 g, 32.4 mmol), ammonium

carbamate (2.02 g, 25.9 mmol), and (4-methoxyphenyl)(methyl)sulfane (2.0 g, 13.0 mmol) in MeOH (32 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, product eluted at 100%) afforded **2b** (1.70 g, 71%) as an orange oil; $R_f = 0.21$ (100% EtOAc); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.93–7.91 (d, $J = 8.9$ Hz, 2H), 7.00–6.98 (d, $J = 8.9$ Hz, 2H), 3.87 (s, 3H), 3.08 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 163.3, 134.9, 129.88 (2 \times C), 114.4 (2 \times C), 55.7, 46.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_8\text{H}_{12}\text{NO}_2\text{S}^+ [\text{M} + \text{H}]^+$, 186.0583; found, 186.0581. Analytical data are in agreement with those reported in the literature.⁵⁷

tert-Butyl (Methyl(oxo)(phenyl)- λ^6 -sulfaneylidene)carbamate (**3a**)

The title compound was prepared according to General Procedure B employing sulfoximine **2a** (400 mg, 2.58 mmol). Purification via flash chromatography (KP-Sil, 0% grading to 10% EtOAc/pentane, product eluted at 8%) afforded sulfoximine **3a** (578 mg, 57%) as a clear oil; $R_f = 0.20$ (15% EtOAc/pentane); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.87–7.85 (m, 2H), 7.71–7.69 (m, 2H), 7.65–7.63 (m, 2H), 7.46–7.42 (m, 1H), 7.39–7.35 (m, 2H), 7.30–7.21 (m, 6H), 2.78 (s, 3H), 1.02 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 144.5, 136.23, 136.19, 135.64 (2 \times C), 135.60 (2 \times C), 132.2, 129.1, 128.9, 128.9 (2 \times C), 127.44 (2 \times C), 127.41 (2 \times C), 127.0, (2 \times C), 49.0, 27.2, 19.41 (3 \times C). HRMS (ESI-TOF) m/z : calcd for $\text{C}_{23}\text{H}_{28}\text{NOSiS}^+ [\text{M} + \text{H}]^+$, 394.1655; found, 394.1657. Analytical data in agreement with those reported in the literature.⁵⁸

(*tert*-Butyldiphenylsilyl)imino(4-methoxyphenyl)(methyl)- λ^6 -sulfanone (**3b**)

The title compound was prepared according to General Procedure B employing sulfoximine **2b** (1.70 g, 2.58 mmol). Purification via flash chromatography (KP-Sil, 0% grading to 20% EtOAc/pentane, product eluted at 15%) afforded sulfoximine **3b** (447 mg, 41%) as an off-white solid; $R_f = 0.20$ (10% EtOAc/pentane); mp (chloroform) = 83–85 $^\circ\text{C}$; IR (film)/ cm^{-1} 3071, 2929, 2855, 1595, 1498, 1308, 1259, 1155, 1107, 1029, 958, 835, 772, 700, 674; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.85 (d, $J = 9.1$ Hz, 2H), 7.78–7.76 (m, 2H), 7.73–7.71 (m, 2H), 7.37–7.28 (m, 6H), 3.85 (s, 3H), 2.83 (s, 3H), 1.09 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 162.6, 136.6, 136.5, 136.4, 135.7 (2 \times C), 135.6 (2 \times C), 129.1 (1 \times C), 129.0, 129.1, 127.42 (3 \times C), 127.38 (3 \times C), 113.9 (2 \times C), 55.6, 49.4, 27.2, 19.4 (3 \times C); HRMS (ESI-TOF) m/z : calcd for $\text{C}_{24}\text{H}_{30}\text{NO}_2\text{SSi}^+ [\text{M} + \text{H}]^+$, 424.1767; found, 424.1771.

(*E*)-((*tert*-Butyldiphenylsilyl)imino)(phenyl)(styryl)- λ^6 -sulfanone (**4a**)

The title compound was prepared according to General Procedure C employing sulfoximine **3a** (200 mg, 0.51 mmol) in anhydrous THF (3.2 mL), *n*BuLi (1.3 M in hexane, 1.05 mL, 1.37 mmol), diisopropylamine (0.11 mL, 0.72 mmol) in THF (3.2 mL), diethylchlorophosphate (0.14 mL, 0.66 mmol), *t*BuOK (1.0 M in THF, 0.66 mL, 0.66 mmol), and benzaldehyde (0.10 mL, 1.02 mmol) in THF (8 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, eluted at 9% EtOAc) afforded vinyl sulfoximine **4a** (147 mg, 60%) as a clear oil; $R_f = 0.49$ (10% EtOAc/pentane); IR (film)/ cm^{-1} 3064, 2930, 2855, 1677, 1614, 1293, 1148, 1107, 969, 816, 745, 700; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.87–7.85 (m, 2H), 7.71–7.65 (m, 4H), 7.44–7.40 (m, 1H), 7.37–7.33 (m, 3H), 7.31 (d, $J = 15.2$ Hz, 1H), 7.26–7.20 (m, 8H), 7.14–7.12 (m, 2H), 6.53 (d, $J = 15.2$ Hz), 1.05 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 144.3, 138.9, 136.4, 136.3, 135.69 (2 \times C), 135.66 (2 \times C), 134.8, 133.0, 132.0, 131.9, 130.3 (2 \times C), 128.9 (2 \times C), 128.8 (3 \times C), 128.3 (2 \times C), 27.2, 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{30}\text{H}_{32}\text{NOSiS}^+ [\text{M} + \text{H}]^+$, 482.1968; found, 482.1982.

(*E*)-((*tert*-Butyldiphenylsilyl)imino)(2-cyclohexylvinyl)(phenyl)- λ^6 -sulfanone (**4b**)

The title compound was prepared according to General Procedure C employing sulfoximine **3a** (200 mg, 0.51 mmol) in anhydrous THF (3.2 mL), *n*BuLi (1.3 M in hexane, 1.05 mL, 1.37 mmol), diisopropylamine (0.1 mL, 0.77 mmol) in anhydrous THF (3.2 mL), diethylchlorophosphate (0.09 mL, 0.66 mmol), *t*BuOK (1.0 M in THF, 0.66 mL, 0.66 mmol), and cyclohexanecarboxaldehyde (0.12 mL, 1.02 mmol) in anhydrous THF (8.0 mL). Purification via flash chromatography (KP-Sil, 0% grading to 10% EtOAc/pentane, eluted

at 7% EtOAc) afforded **4b** (142 mg, 57%) as a clear yellow oil; $R_f = 0.66$ (10% EtOAc/pentane); IR (film)/ cm^{-1} 3067, 2929, 2855, 1319, 1159, 1107, 820, 745, 700; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.80–7.78 (m, 2H), 7.68–7.63 (m, 4H), 7.42–7.38 (m, 1H), 7.35–7.32 (m, 2H), 7.29–7.21 (m, 6H), 6.62–6.57 (dd, $J = 6.2, 8.6$ Hz), 5.98–5.94 (dd, $J = 1.5, 13.4$ Hz), 1.89–1.82 (m, 2H), 1.60–1.45 (m, 6H), 1.18–1.05 (m, 2H), 1.02 (s, 9H), 0.89–0.76 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 147.9, 144.6, 136.6, 136.5, 135.7 (2 \times C), 135.6 (2 \times C), 132.3 (2 \times C), 131.7, 128.9 (2 \times C), 128.7 (3 \times C), 127.3 (2 \times C), 127.2 (2 \times C), 39.3, 31.3 (2 \times C), 27.2 (3 \times C), 25.8 (2 \times C), 25.5, 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{30}\text{H}_{38}\text{NOSSi}^+ [\text{M} + \text{H}]^+$, 488.2443; found, 488.2447.

(*E*)-((*tert*-Butyldiphenylsilyl)imino)(4-ethynylstyryl)(phenyl)- λ^6 -sulfanone (**4c**)

The title compound was prepared according to General Procedure C employing sulfoximine **3a** (600 mg, 0.51 mmol) in THF (9.6 mL), *n*BuLi (1.3 M in hexane, 3.10 mL, 4.14 mmol), diisopropylamine (0.30 mL, 2.25 mmol) in THF (9.6 mL), diethylchlorophosphate (0.30 mL, 1.98 mmol), *t*BuOK (1.0 M in THF, 1.98 mL, 1.98 mmol), and 4-ethynylbenzaldehyde (392 mg, 3.04 mmol) in THF (20 mL). Purification via flash chromatography (KP-Sil, 0% grading to 10% EtOAc/pentane, eluted at 8% EtOAc) afforded **4c** (175 mg, 68%) as an orange oil; IR (film)/ cm^{-1} 3067, 2925, 2851, 1325, 1160, 1107, 821, 745; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.95–7.93 (m, 2H), 7.77–7.72 (m, 4H), 7.54–7.48 (m, 1H), 7.46–7.44 (m, 2H), 7.41–7.38 (m, 2H), 7.34–7.27 (m, 6H), 7.13–7.11 (m, 2H), 6.57 (d, $J = 15.1$ Hz, 1H), 3.16 (s, 1H), 1.13 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 144.1, 137.6, 136.3, 136.2, 135.69 (2 \times C), 135.66 (2 \times C), 133.4, 132.8, 132.4 (2 \times C), 132.2, 129.0 (2 \times C), 128.9 (2 \times C), 128.1 (2 \times C), 127.5 (2 \times C), 127.43 (2 \times C), 127.39 (2 \times C), 123.9, 83.0, 79.2, 27.2, 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{32}\text{H}_{32}\text{NOSSi}^+ [\text{M} + \text{H}]^+$, 506.1968; found, 506.1970.

(*E*)-((*tert*-Butyldiphenylsilyl)imino)(phenyl)(2-(pyridin-2-yl)vinyl)- λ^6 -sulfanone (**4d**)

The title compound was prepared according to General Procedure C employing sulfoximine **3a** (200 mg, 0.51 mmol) in anhydrous THF (3.2 mL), *n*BuLi (1.3 M in hexane, 1.05 mL, 1.37 mmol), diisopropylamine (0.10 mL, 0.77 mmol) in THF (3.2 mL), diethylchlorophosphate (0.09 mL, 0.66 mmol), *t*BuOK (1.0 M in THF, 0.66 mL, 0.66 mmol), and picolinaldehyde (0.12 mL, 1.02 mmol) in THF (8 mL). Purification via flash chromatography (KP-Sil, 0% grading to 20% EtOAc/petroleum ether, eluted at 20% EtOAc) afforded **4d** (148 mg, 60%) as a yellow oil; $R_f = 0.19$ (10% EtOAc/petroleum ether); IR (film)/ cm^{-1} 3067, 2929, 2855, 1580, 1468, 1427, 1327, 1170, 1107, 820, 704; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.54–8.53 (d, $J = 4.6$ Hz, 1H), 7.97–7.94 (m, H), 7.80–7.74 (m, 4H), 7.64–7.60 (m, 1H), 7.50–7.44 (m, 1H), 7.40–7.36 (m, 2H), 7.32 (d, $J = 15.2$ Hz), 7.32–7.27 (m, 5H), 7.25–7.18 (m, 2H), 7.13–7.11 (d, $J = 7.8$ Hz, 1H), 1.14 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 151.9, 150.0, 143.8, 137.1, 136.7, 136.3, 135.7 (2 \times C), 135.7 (2 \times C), 132.2, 128.9 (3 \times C), 127.6 (2 \times C), 127.4 (2 \times C), 127.3 (2 \times C), 124.8, 124.2, 27.3 (3 \times C), 19.5. HRMS (ESI-TOF) m/z : calcd for $\text{C}_{29}\text{H}_{31}\text{N}_2\text{OSSi}^+ [\text{M} + \text{H}]^+$, 483.1926; found, 483.1931.

(*E*)-((*tert*-Butyldiphenylsilyl)imino)(4-ethynylstyryl)(4-methoxyphenyl)- λ^6 -sulfanone (**4e**)

The title compound was prepared according to General Procedure C employing sulfoximine **3b** (200 mg, 0.47 mmol) in THF (3.2 mL), *n*BuLi (1.3 M in hexane, 1.05 mL, 1.37 mmol), diisopropylamine (0.10 mL, 0.77 mmol) in THF (3.2 mL), diethylchlorophosphate (0.09 mL, 0.66 mmol), *t*BuOK (1.0 M in THF, 0.66 mL, 0.66 mmol), and ethynylbenzaldehyde (123 mg, 0.94 mmol) in THF (8 mL). Purification via flash chromatography (KP-Sil, 0% grading to 20% EtOAc/petroleum ether, eluted at 12% EtOAc) afforded **4e** (128 mg, 51%) as a clear oil; $R_f = 0.35$ (20% EtOAc/pentane); IR (film)/ cm^{-1} 3291, 2929, 2855, 1595, 1495, 1312, 1259, 1148, 1107, 1028, 805, 704; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.85 (d, $J = 8.9$ Hz, 2H), 7.77–7.71 (m, 4H), 7.37 (d, $J = 8.4$ Hz, 2H), 7.35–7.24 (m, 7H), 7.09 (d, $J = 8.4$ Hz, 2H), 6.90 (d, $J = 8.9$ Hz, 2H), 6.56 (d, $J = 15.2$ Hz, 1H), 3.84 (s, 3H), 3.16 (s, 3H), 1.12 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz,

CDCl_3) δ 162.6 (2 \times C), 136.7, 136.5, 136.3, 135.8, 135.7 (3 \times C), 133.5, 133.4, 132.4 (2 \times C), 129.6 (2 \times C), 129.0 (2 \times C), 128.0 (2 \times C), 127.4 (4 \times C), 123.7, 114.1 (2 \times C), 83.1, 79.1, 55.6, 27.2 (3 \times C), 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{33}\text{H}_{34}\text{NO}_2\text{Si}^+$ [M + H]⁺, 536.2080; found, 536.2074.

(*E*)-((*tert*-Butyldiphenylsilyl)imino)(4-methoxyphenyl)(2-(thiazol-2-yl)vinyl)- λ^6 -sulfanone (**4f**)

The title compound was prepared according to General Procedure C employing sulfoximine **3b** (300 mg, 0.71 mmol) in THF (4.8 mL), *n*BuLi (1.3 M in hexane, 1.50 mL, 1.91 mmol), diisopropylamine (0.15 mL, 1.07 mmol) in THF (4.8 mL), diethylchlorophosphate (0.13 mL, 0.92 mmol), *t*BuOK (1.0 M in THF, 0.92 mL, 0.92 mmol), and 1,3-thiazole-2-carbaldehyde (0.13 mL, 1.42 mmol) in THF (10 mL). Purification via flash chromatography (KP-Sil, 0% grading to 50% EtOAc/hexane, eluted at 30% EtOAc) afforded **4f** (311 mg, 84%) as a yellow oil; R_f = 0.38 (EtOAc/hexane); IR (film)/ cm^{-1} 3071, 2959, 2855, 1595, 1494, 1312, 1259, 1151, 1107, 1028, 820, 704; ¹H NMR (400 MHz, CDCl_3) δ 7.85 (d, J = 8.7 Hz, 2H), 7.81 (d, J = 3.2 Hz, 1H), 7.78–7.72 (m, 4H), 7.37 (d, J = 15.3 Hz), 7.35 (d, J = 3.32 Hz, 1H), 7.32–7.28 (m, 6H), 6.96 (d, J = 15.3 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 162.9, 162.0, 144.5, 137.1, 136.1 (2 \times C), 135.7 (4 \times C), 135.0, 129.9 (2 \times C), 129.0, 128.7, 127.4 (6 \times C), 121.4, 114.2 (2 \times C), 55.6, 27.3 (3 \times C), 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{28}\text{H}_{31}\text{N}_2\text{O}_2\text{S}_2\text{Si}^+$ [M + H]⁺, 519.1591; found, 519.1599.

(*E*)-((*tert*-Butyldiphenylsilyl)imino)(4-methoxyphenyl)(2-(quinoxalin-2-yl)vinyl)- λ^6 -sulfanone (**4g**)

The title compound was prepared according to General Procedure C employing sulfoximine **3b** (300 mg, 0.71 mmol) in anhydrous THF (4.8 mL), *n*BuLi (1.3 M in hexane, 1.50 mL, 1.91 mmol), diisopropylamine (0.15 mL, 1.07 mmol) in THF (4.8 mL), diethylchlorophosphate (0.13 mL, 0.92 mmol), *t*BuOK (1.0 M in THF, 0.92 mL, 0.92 mmol), and quinoxaline-2-carbaldehyde (200 mg, 1.42 mmol) in THF (10 mL). Purification via flash chromatography (KP-Sil, 0% grading to 50% EtOAc/hexane, eluted at 26% EtOAc/hexane) afforded **4g** (271 mg, 68%) as an orange oil; R_f = 0.33 (40% EtOAc/hexane); IR (film)/ cm^{-1} 3071, 2963, 2855, 1595, 1494, 1312, 1259, 1148, 1107, 1058, 820, 764, 704; ¹H NMR (400 MHz, CDCl_3) δ 8.55 (s, 1H), 8.07–8.05 (m, 1H), 8.00–7.97 (m, 1H), 7.93 (d, J = 8.9 Hz, 2H), 7.80–7.74 (m, 6H), 7.38 (d, J = 15.3 Hz, 1H), 7.28 (d, J = 15.3 Hz, 1H), 7.28–7.26 (m, 6H), 6.94 (d, J = 8.81 Hz, 2H), 3.85 (s, 3H), 1.15 (s, 9H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 163.0, 147.2, 144.9, 142.3 (2 \times C), 139.7, 136.1, 135.7 (4 \times C), 134.9, 132.9, 130.7 (2 \times C), 130.1 (2 \times C), 129.6, 129.2, 129.1 (2 \times C), 127.4 (6 \times C), 114.3 (2 \times C), 55.7, 27.3 (3 \times C), 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{33}\text{H}_{34}\text{N}_3\text{O}_2\text{Si}^+$ [M + H]⁺, 564.2141; found, 564.2154.

(*E*)-Imino(phenyl)(styryl)- λ^6 -sulfanone (**5a**)

The title compound was prepared according to General Procedure D employing vinyl sulfoximine **4a** (125 mg, 0.26 mmol) and TBAF (1.0 M in THF, 0.29 mL, 0.29 mmol) in anhydrous THF (4.7 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, eluted at 58% EtOAc) gave vinyl sulfoximine **5a** as a yellow oil (47 mg, 74%); R_f = 0.58 (100% EtOAc); ¹H NMR (400 MHz, CDCl_3) δ 8.05–8.02 (m, 2H), 7.62 (d, J = 15.2 Hz, 1H), 7.60–7.56 (m, 1H), 7.55–7.51 (m, 2H), 7.49–7.46 (m, 2H), 7.40–7.37 (m, 3H), 6.93 (d, J = 15.3 Hz, 1H), 2.68 (bs, 1H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 142.8, 141.6, 132.8, 132.7, 130.9, 129.5, 129.2 (2 \times C), 129.0 (2 \times C), 128.5 (2 \times C), 127.9 (2 \times C); HRMS (ESI-TOF) m/z : calcd for $\text{C}_{14}\text{H}_{14}\text{NOS}^+$ [M + H]⁺, 244.0807; found, 244.0796. Analytical data are in agreement with those reported in the literature.²²

(*E*)-(2-Cyclohexylvinyl)(imino)(phenyl)- λ^6 -sulfanone (**5b**)

The title compound was prepared according to General Procedure D employing vinyl sulfoximine **4b** (115 mg, 0.24 mmol) and TBAF (1.0 M in THF, 0.26 mL, 0.26 mmol) in THF (4.5 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, eluted at 50% EtOAc) afforded **5b** (44 mg, 74%) as a yellow oil; R_f = 0.42 (50% EtOAc/pentane); IR (film)/ cm^{-1} 3270, 2924, 2851, 1625, 1446, 1226, 1125, 969, 7511, 688; ¹H NMR (400 MHz,

CDCl_3) δ 7.96–7.93 (m, 2H), 7.59–7.55 (m, 1H), 7.52–7.48 (m, 2H), 6.86 (dd, J = 8.7 Hz, 6.5 Hz), 6.30 (dd, J = 14.1 Hz, 1.4 Hz, 1H), 2.44 (bs, 1H), 2.20–2.13 (m, 1H), 1.75–1.72 (m, 4H), 1.67–1.64 (m, 1H), 1.31–1.06 (m, 5H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 150.7, 143.1, 132.6, 130.0, 129.10 (2 \times C), 127.7 (2 \times C), 39.8 (1 \times C), 31.4, 31.3, 25.8 (2 \times C), 25.6 (1 \times C); HRMS (ESI) m/z : calcd for $\text{C}_{14}\text{H}_{20}\text{NOS}^+$ [M + H]⁺, 250.1266; found, 250.1263.

(*E*)-(4-Ethynylstyryl)(imino)(phenyl)- λ^6 -sulfanone (**5c**)

The title compound was prepared according to General Procedure D employing vinyl sulfoximine **4c** (690 mg, 1.37 mmol) and TBAF (1.0 M in THF, 50 mL, 1.51 mmol) in THF (25 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, eluted at 50% EtOAc) afforded **5c** (300 mg, 82%) as a white solid; R_f = 0.43 (50% EtOAc/pentane); mp (CHCl_3) 133–135 °C; IR (film)/ cm^{-1} 3279, 3061, 2579, 2361, 1614, 1445, 1217, 1125, 974, 799, 753, 687; ¹H NMR (400 MHz, CDCl_3) δ 8.04–8.02 (m, 2H), 7.62–7.57 (m, 2H), 7.56–7.52 (m, 2H), 7.47 (d, J = 8.5 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 15.3 Hz, 1H), 3.19 (s, 1H), 2.95 (bs, 1H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 142.5, 140.4, 133.0, 132.7 (2 \times C), 130.5, 129.3 (2 \times C), 128.3 (2 \times C), 128.0 (2 \times C), 124.6, 82.9, 79.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{16}\text{H}_{14}\text{NOS}^+$ [M + H]⁺, 268.0796; found, 268.0804.

(*E*)-Imino(phenyl)(2-(pyridin-2-yl)vinyl)- λ^6 -sulfanone (**5d**)

The title compound was prepared according to General Procedure D employing vinyl sulfoximine **4d** (70 mg, 0.15 mmol) and TBAF (1.0 M in THF, 0.16 mL, 0.16 mmol) in THF (2.8 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/petroleum ether, eluted at 100% EtOAc) afforded **5d** (25 mg, 69%) as a white solid; R_f = 0.39 (100% EtOAc); mp (CHCl_3) = 94–96 °C; IR (film)/ cm^{-1} 3258, 3056, 1580, 1469, 1431, 1215, 1111, 969, 797, 753, 708; ¹H NMR (400 MHz, CDCl_3) δ 8.60–8.59 (d, J = 4.5 Hz, 1H), 8.06–8.04 (m, 2H), 7.69 (m, 1H), 7.60 (d, J = 15.2 Hz, 1H), 7.59–7.54 (m, 1H), 7.54–7.51 (m, 2H), 7.46 (d, J = 15.3 Hz, 1H), 7.40–7.38 (d, J = 7.8 Hz, 1H), 2.67 (bs, 1H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 151.4, 150.2, 142.0, 139.6, 137.0, 134.2, 133.0 (2 \times C), 129.2 (2 \times C), 128.2, 125.2, 124.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{13}\text{H}_{13}\text{N}_2\text{OS}^+$ [M + H]⁺, 245.0749; found, 245.0755. Analytical data are in agreement with those reported in the literature.²²

(*E*)-(4-Ethynylstyryl)(imino)(4-methoxyphenyl)- λ^6 -sulfanone (**5e**)

The title compound was prepared according to General Procedure D employing vinyl sulfoximine **4e** (70 mg, 0.15 mmol) and TBAF (1.0 M in THF, 0.16 mL, 0.16 mmol) in THF (2.8 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/petroleum ether, eluted at 48% EtOAc) afforded **5e** (32 mg, 72%) as an orange oil; R_f = 0.24 (50% EtOAc/petroleum ether); IR (film)/ cm^{-1} 3283, 3049, 2940, 2840, 1595, 1494, 1461, 1312, 1259, 1215, 1177, 1110, 976, 805; ¹H NMR (400 MHz, CDCl_3) δ 7.95–7.93 (d, J = 8.6 Hz, 2H), 7.52 (d, J = 15.4 Hz, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.0, 2H), 6.98 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 15.4 Hz, 1H), 3.85 (s, 3H), 3.18 (s, 1H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 163.3, 139.4, 133.8, 133.1, 132.6 (2 \times C), 131.1, 130.2 (2 \times C), 128.2 (2 \times C), 124.4, 114.5 (2 \times C), 82.9, 79.5, 55.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_2\text{S}^+$ [M + H]⁺, 298.0902; found, 298.0895.

(*E*)-Imino(4-methoxyphenyl)(2-(thiazol-2-yl)vinyl)- λ^6 -sulfanone (**5f**)

The title compound was prepared according to General Procedure D employing vinyl sulfoximine **4f** (250 mg, 0.48 mmol) and TBAF (1.0 M in THF, 0.53 mL, 0.53 mmol) in THF (9 mL). Purification via flash chromatography (KP-Sil, 0% grading to 100% EtOAc/hexane, eluted at 80% EtOAc) afforded **5f** (114 mg, 85%) as a yellow oil; R_f = 0.40 (80% EtOAc/hexane); IR (film)/ cm^{-1} 3259, 2926, 2840, 1593, 1494, 1312, 1258, 1231, 1126, 1108, 1090, 1021, 833; ¹H NMR (400 MHz, CDCl_3) δ 7.94 (d, J = 8.94 Hz, 2H), 7.88 (d, J = 3.2 Hz, 1H), 7.65 (d, J = 15.2 Hz, 1H), 7.44 (d, J = 3.2 Hz, 1H), 7.24 (d, J = 15.3 Hz, 1H), 6.98 (d, J = 9.0 Hz, 2H), 3.86 (s, 3H), 2.93 (bs, 1H); ¹³C{¹H} NMR (101 Hz, CDCl_3) δ 163.6, 161.4, 144.9, 135.0, 132.8, 131.1, 130.5 (2 \times C), 127.1, 122.1, 114.6 (2 \times C), 55.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2\text{S}_2^+$ [M + H]⁺, 281.0418; found, 281.0410.

(*E*)-Imino(4-methoxyphenyl)(2-(quinoxalin-2-yl)vinyl)- λ^6 -sulfanone (**5g**)

The title compound was prepared according to General Procedure D employing vinyl sulfoximine **4g** (270 mg, 0.48 mmol) and TBAF (1.0 M in THF, 0.53 mL, 0.53 mmol) in THF (9.0 mL). Purification by flash chromatography (KP-Sil, 0% grading to 100% EtOAc/hexane, eluted at 90% EtOAc) afforded **5g** (120 mg, 77%) as a brown oil; $R_f = 0.51$ (100% EtOAc/hexane); IR (film)/ cm^{-1} 3250, 3060, 2840, 1591, 1491, 1413, 1364, 1256, 1230, 1178, 1126, 1013, 969, 827, 760, 670; ^1H NMR (400 MHz, CDCl_3) δ 8.93 (s, 1H), 8.10–8.07 (m, 1H), 8.04–8.00 (m, 3H), 7.81–7.77 (m, 3H), 7.67 (d, $J = 15.2$ Hz), 7.00–7.03 (m, 2H), 3.87 (s, 3H), 3.04 (bs, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 163.6, 146.7, 145.0, 142.6, 142.3, 137.8, 135.5, 132.8, 131.0, 130.9, 130.6 (2 \times C), 129.7, 129.3, 127.1, 114.6 (2 \times C), 55.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{17}\text{H}_{16}\text{N}_3\text{O}_2\text{S}^+$ [$\text{M} + \text{H}$] $^+$, 326.0958; found, 326.0974.

Enantioenriched Vinyl Sulfoximines (S)-5h and (R)-5h. (S)-Imino(methyl)(*p*-tolyl)- λ^6 -sulfanone ((S)-2h). The title compound was prepared according to General Procedure E employing (S)-1-methyl-4-(methylsulfinyl)benzene (**S-6**) (500 mg, 3.13 mmol, er >99:1). Purification by flash chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, product eluted at 100%) afforded (**S-2h**) (473 mg, 86%) as a clear oil; $R_f = 0.20$ (100% EtOAc); ^1H NMR (400 MHz, CDCl_3) δ 7.90–7.88 (m, 2H), 7.34 (d, $J = 8.0$ Hz, 2H), 3.09 (s, 3H), 2.45 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 144.0, 140.5, 129.9 (2 \times C), 127.7 (2 \times C), 46.3, 21.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_8\text{H}_{11}\text{NOS}^+$ [$\text{M} + \text{H}$] $^+$, 170.0640; found, 170.0642. Analytical data are in agreement with those reported in the literature.³¹

(R)-Imino(methyl)(*p*-tolyl)- λ^6 -sulfanone ((R)-2h). The title compound was prepared according to General Procedure E employing (R)-1-methyl-4-(methylsulfinyl)benzene (250 mg, 1.62 mmol, er >99:1). Purification by flash column chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, product eluted at 100%) afforded (**R-2h**) (255 mg, 94%) as a clear oil. $R_f = 0.20$ (100% EtOAc); ^1H NMR (400 MHz, CDCl_3) δ 7.90–7.88 (m, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 3.11 (s, 3H), 2.43 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 143.9, 140.5, 129.9 (2 \times C), 127.7 (2 \times C), 46.4, 21.6; HRMS (ESI-TOF) m/z : calcd for $\text{C}_8\text{H}_{11}\text{NOS}^+$ [$\text{M} + \text{H}$] $^+$, 170.0640; found, 170.0641. Analytical data are in agreement with those reported in the literature.⁵⁹

(S)-((tert-Butyldiphenylsilyl)imino)(methyl)(*p*-tolyl)- λ^6 -sulfanone ((S)-3h). The title compound was prepared according to General Procedure B employing (**S-2h**) (531 mg, 3.14 mmol). Purification by flash chromatography (KP-Sil, 0% grading to 10% EtOAc/pentane, product eluted at 10%) afforded (**S-3h**) (830 mg, 65%, >99:1 er) as a clear oil; $R_f = 0.43$ (10% EtOAc/pentane); IR (film)/ cm^{-1} 3049, 2955, 2855, 1599, 1427, 1427, 1326, 1293, 1162, 1107, 964, 820, 767, 741, 700; ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.80 (m, 2H), 7.78–7.76 (m, 2H), 7.73–7.70 (m, 2H), 7.41–7.28 (m, 6H), 7.23 (d, $J = 8.1$ Hz, 2H), 2.83 (s, 3H), 2.40 (s, 3H), 1.09 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 138.2, 136.5, 135.64 (2 \times C), 135.58 (2 \times C), 134.8, 129.7, 129.5 (2 \times C), 129.0 (3 \times C), 127.4, 127.0 (2 \times C) 49.1, 27.2 (9 \times C), 21.46, 19.40; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{24}\text{H}_{30}\text{NOSSi}^+$ [$\text{M} + \text{H}$] $^+$, 408.1817; found, 408.1834.

(R)-((tert-Butyldiphenylsilyl)imino)(methyl)(*p*-tolyl)- λ^6 -sulfanone ((R)-3h). The title compound was prepared according to General Procedure B employing (**R-2h**) (236 mg, 1.39 mmol). Purification by flash column chromatography (KP-Sil, 0% grading to 10% EtOAc/pentane, product eluted at 10%) afforded (**R-3h**) (346 mg, 61%, er >99:1) as a clear oil; $R_f = 0.43$ (10% EtOAc/pentane) IR (film)/ cm^{-1} 3067, 2955, 2855, 1590, 1472, 1427, 1323, 1293, 1162, 1107, 954, 820, 768, 741, 700; ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.80 (m, 2H), 7.78–7.76 (m, 2H), 7.73–7.70 (m, 2H), 7.37–7.29 (m, 6H), 7.23 (d, $J = 9.0$ Hz, 2H), 2.83 (s, 3H), 2.40 (s, 3H), 1.09 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 138.2, 136.5, 135.6 (4 \times C), 134.8, 129.7, 129.5 (2 \times C), 129.0 (3 \times C), 127.4, 127.0 (2 \times C) 49.1, 27.2 (9 \times C), 21.5, 19.4; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{24}\text{H}_{30}\text{NOSSi}^+$ [$\text{M} + \text{H}$] $^+$, 408.1817; found, 408.1828.

(S,E)-((tert-Butyldiphenylsilyl)imino)(4-ethynylstyryl)(*p*-tolyl)- λ^6 -sulfanone ((S)-4h). The title compound was prepared according to General Procedure C employing sulfoximine (**S-3h**) (100 mg, 0.25 mmol, er >99:1) in THF (1.6 mL), *n*BuLi (1.3 M in hexane, 0.52 mL, 0.68 mmol), diisopropylamine (0.05 mL, 0.37 mmol) in THF (1.6 mL), diethylchlorophosphate (0.05 mL, 0.32 mmol), *t*BuOK (1.0 M in THF, 0.32 mL, 0.32 mmol), and 4-ethynylbenzaldehyde (85 mg, 0.47 mmol) in THF (4 mL). Purification by flash chromatography (KP-Sil, 0% grading to 10% EtOAc/hexane, product eluted at 8% EtOAc) afforded (**S-4h**) (88 mg, 69%, er >99:1) as a yellow oil; $R_f = 0.22$ (10% EtOAc/hexane); IR (film)/ cm^{-1} 3291, 3049, 2955, 2855, 1595, 1468, 1427, 1312, 1148, 1107, 1017, 969, 797, 741, 700; ^1H NMR (400 MHz, CDCl_3) δ 7.83 (d, $J = 8.3$ Hz, 2H), 7.79–7.73 (m, 5H), 7.39 (d, $J = 8.1$ Hz, 2H), 7.37–7.24 (m, 8H), 7.10 (d, $J = 8.3$ Hz, 2H), 6.57 (d, $J = 15.3$ Hz, 1H), 3.17 (s, 1H), 2.40 (s, 3H), 1.14 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 142.9, 141.2, 137.2, 136.5, 136.3, 135.7 (2 \times C), 134.8, 133.5, 133.2, 132.4, 129.6 (2 \times C), 129.0, 128.1, 127.7, 127.6, 127.4 (2 \times C), 123.8, 83.1, 79.2, 27.2 (9 \times C), 21.5, 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{33}\text{H}_{34}\text{NOSSi}^+$ [$\text{M} + \text{H}$] $^+$, 520.2131; found, 520.2120.

(R,E)-((tert-Butyldiphenylsilyl)imino)(4-ethynylstyryl)(*p*-tolyl)- λ^6 -sulfanone ((R)-4h). The title compound was prepared according to General Procedure C employing sulfoximine (**R-3h**) (100 mg, 0.25 mmol, er >99:1) in THF (1.6 mL), *n*BuLi (1.3 M in hexane, 0.52 mL, 0.68 mmol), diisopropylamine (0.05 mL, 0.37 mmol) in THF (1.6 mL), diethylchlorophosphate (0.05 mL, 0.32 mmol), *t*BuOK (1.0 M in THF, 0.32 mL, 0.32 mmol), and 4-ethynylbenzaldehyde (85 mg, 0.47 mmol) in THF (4 mL). Purification by flash column chromatography (KP-Sil, 0% grading to 10% EtOAc/hexane, product eluted at 8% EtOAc) afforded (**R-4h**) (81 mg, 62%, er >99:1) as a yellow oil; $R_f = 0.17$ (10% EtOAc/hexane); IR (film)/ cm^{-1} 3291, 3049, 2955, 2855, 1681, 1554, 1472, 1427, 1312, 1151, 1107, 1017, 972, 801, 741, 704; ^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, $J = 8.3$ Hz, 2H), 7.78–7.72 (m, 5H), 7.38 (d, $J = 8.4$ Hz, 2H), 7.33–7.23 (m, 8H), 7.10 (d, $J = 8.3$ Hz, 2H), 6.57 (d, $J = 15.3$ Hz, 1H), 3.16 (s, 1H), 2.40 (s, 3H), 1.13 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 142.9, 141.2, 137.2, 136.5, 136.3, 135.7 (2 \times C), 134.8, 133.5, 133.2, 132.4, 129.6 (2 \times C), 129.0, 128.1, 127.7, 127.6, 127.4 (2 \times C), 123.7, 83.1, 79.2, 27.2 (9 \times C), 21.5, 19.5; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{33}\text{H}_{34}\text{NOSSi}^+$ [$\text{M} + \text{H}$] $^+$, 520.2131; found, 520.2130.

(S,E)-(4-Ethynylstyryl)imino(*p*-tolyl)- λ^6 -sulfanone ((S)-5h). The title compound was prepared according to General Procedure D employing sulfoximine (**S-4h**) (80 mg, 0.15 mmol, er >99:1). Purification by flash column chromatography (KP-Sil, 0% grading to 100% EtOAc/hexane, product eluted at 48% EtOAc) afforded (**S-5h**) (39 mg, 92%, er >99:1) as an off-white solid; $R_f = 0.34$ (50% EtOAc/hexane); mp (CHCl_3) = 147–149 $^\circ\text{C}$; IR (film)/ cm^{-1} 3280, 3045, 1599, 1408, 1215, 1114, 1080, 976, 861, 797, 756; ^1H NMR (400 MHz, CDCl_3) δ 7.90 (d, $J = 8.4$ Hz, 2H), 7.56 (d, $J = 15.3$ Hz, 1H), 7.47 (d, $J = 8.7$ Hz, 2H), 7.41 (d, $J = 8.6$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 2H), 6.93 (d, $J = 15.2$ Hz, 1H), 3.19 (s, 1H), 2.43 (s, 3H), 2.38 (bs, 1H, NH); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 143.9, 139.9, 139.5, 133.0, 132.7 (2 \times C), 130.7, 130.0 (2 \times C), 128.3 (2 \times C), 128.0 (2 \times C), 124.4, 82.9, 79.6, 21.56; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{17}\text{H}_{16}\text{NOS}^+$ [$\text{M} + \text{H}$] $^+$, 282.0953; found, 282.0952.

(R,E)-(4-Ethynylstyryl)imino(*p*-tolyl)- λ^6 -sulfanone ((R)-5h). The title compound was prepared according to General Procedure D employing sulfoximine (**R-4h**) (40 mg, 0.08 mmol, er >99:1). Purification by flash column chromatography (KP-Sil, 0% grading to 100% EtOAc/hexane, product eluted at 48% EtOAc) afforded (**R-5h**) (17 mg, 79%, er >99:1) as an off-white solid; $R_f = 0.34$ (50% EtOAc/hexane); mp (CHCl_3) = 147–149 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, $J = 8.4$ Hz, 2H), 7.56 (d, $J = 15.3$ Hz, 1H), 7.47 (d, $J = 8.3$ Hz, 2H), 7.40 (d, $J = 8.3$ Hz, 2H), 7.32 (d, $J = 8.3$ Hz, 2H), 6.92 (d, $J = 15.2$ Hz, 1H), 3.18 (s, 1H), 2.43 (s, 3H), 2.40 (bs, 1H, NH); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 144.0, 140.0, 133.0 (2 \times C), 132.7 (2 \times C), 130.7, 130.0 (2 \times C), 128.3 (2 \times C), 128.1 (2 \times C), 124.5, 82.9, 79.6, 21.6; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{17}\text{H}_{16}\text{NOS}^+$ [$\text{M} + \text{H}$] $^+$, 282.0953; found, 282.0952.

(*E*)-Trimethyl(2-(phenylthio)vinyl)silane (**9a**). The title compound was prepared according to General Procedure F employing RhCl(PPh₃)₃ (46 mg, 0.05 mmol), ethynyltrimethylsilane (0.14 mL, 1.0 mmol), and thiophenol (102 μL, 1.0 mmol). Purification by flash column chromatography (KP-Sil, hexane) afforded vinyl sulfide **9a** (179 mg, 86%) as a colorless oil; *R*_f = 0.80 (hexane); IR (film)/cm⁻¹ 3061, 2956, 2895, 1546, 1484, 1439, 1234, 1026, 841, 742; ¹H NMR (400 MHz, CDCl₃) δ 7.59–7.01 (m, 5H), 6.59 (d, *J* = 18.0 Hz, 1H), 5.82 (d, *J* = 18.0 Hz, 1H), 0.00 (s, 9H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 145.0, 135.2, 129.4 (2 × C), 129.1 (2 × C), 125.6, 122.8, -0.8 (9 × C); HRMS (atmospheric pressure chemical ionization (APCI)⁺) *m/z*: calcd for C₁₁H₁₇SSi⁺ [M + H]⁺, 209.0815; found, 209.0817. Analytical data are in agreement with those reported in the literature.⁶⁰

(*E*)-(2-(Benzylthio)vinyl)trimethylsilane (**9b**). The title compound was prepared according to General Procedure F employing RhCl(PPh₃)₃ (92 mg, 0.10 mmol), ethynyltrimethylsilane (0.28 mL, 2.0 mmol), and benzyl mercaptan (0.23 mL, 2.0 mmol). Purification by flash column chromatography (SiO₂, hexane) afforded vinyl sulfide **9b** (356 mg, 80%) as a colorless oil; *R*_f = 0.60 (hexane); IR (film)/cm⁻¹ 3060, 3027, 2960, 2922, 2859, 1603, 1548, 1495, 1454, 1416, 1374, 1334, 1200, 1103, 1070, 917, 850, 768, 701; ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.27 (m, 5H), 6.55 (d, *J* = 18.1 Hz, 1H), 5.79 (d, *J* = 18.1 Hz, 1H), 3.95 (s, 2H), 0.06 (s, 9H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 138.3, 137.3, 129.0 (2 × C), 128.7 (2 × C), 127.4, 125.9, 36.1, -1.0 (9 × C); HRMS (APCI)⁺ *m/z*: calcd for C₁₂H₁₈SSi⁺ [M + H]⁺, 222.0893; found, 222.0900.

(*E*)-(4-Methoxystyryl)(naphthalen-2-yl)sulfane (**9c**). The title compound was prepared according to General Procedure F employing RhCl(PPh₃)₃ (46 mg, 0.05 mmol), naphthalene-2-thiol (176 mg, 1.1 mmol), and 1-ethynyl-4-methoxybenzene (129 μL, 1.0 mmol). Purification by flash column chromatography (SiO₂, 5% Et₂O/hexane) afforded vinyl sulfide **9c** (227 mg, 78%) as a white solid; *R*_f = 0.40 (5% Et₂O/hexane); mp = 103–105 °C; IR (film)/cm⁻¹ 3056, 3004, 1602, 1509, 1252, 1032, 950, 846, 801; ¹H NMR (400 MHz, CDCl₃) δ 7.87–7.75 (m, 4H), 7.53–7.44 (m, 3H), 7.38–7.32 (m, 2H), 6.92–6.85 (m, 2H), 6.83 (s, 2H), 3.83 (s, 3H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 159.5, 133.8, 133.4, 133.1, 132.1, 129.4, 128.6, 127.8, 127.5 (2 × C), 127.4, 127.2 (2 × C), 126.6, 125.9, 119.8, 114.2 (2 × C), 55.3; HRMS (APCI)⁺ *m/z*: calcd for C₁₉H₁₇OS⁺ [M + H]⁺, 293.0995; found, 293.1003. Analytical data are in agreement with those reported in the literature.⁶¹

(*E*)-(4-Bromophenyl)(styryl)sulfane (**9d**). The title compound was prepared according to General Procedure F employing RhCl(PPh₃)₃ (92 mg, 0.1 mmol), 4-bromobenzenethiol (378 mg, 2.0 mmol), and ethynylbenzene (0.22 mL, 2.0 mmol). Purification by flash column chromatography (SiO₂, pentane) afforded vinyl sulfide **9b** (576 mg, 99%) as an off-white solid; *R*_f = 0.45 (pentane); mp = 77–78 °C; IR (film)/cm⁻¹ 3079, 3056, 3019, 2933, 1897, 1774, 1737, 1664, 1599, 1472, 1387, 1230, 1088, 1032, 989, 954, 813, 742, 693; ¹H NMR (400 MHz, CDCl₃) δ 7.50–7.42 (m, 2H), 7.39–7.19 (m, 7H), 6.87–6.72 (m, 2H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 136.3, 134.7, 133.1, 132.3 (2 × C), 131.1 (2 × C), 128.8 (2 × C), 128.0, 126.2 (2 × C), 122.3, 120.9; HRMS (APCI)⁺ *m/z*: calcd for C₁₄H₁₂SBr⁺ [M + H]⁺, 290.9838; found, 290.9830.

Butyl (*E*)-3-((4-Bromostyryl)thio)propanoate (**9e**). The title compound was prepared according to an adaptation of General Procedure F, including heating to 65 °C using a heating block and increasing the catalyst loading to 10 mol %, employing RhCl(PPh₃)₃ (92 mg, 0.1 mmol), 1-bromo-4-ethynylbenzene (181 mg, 1.0 mmol), and butyl 3-mercaptopropanoate (178 μL, 1.1 mmol). Purification by flash column chromatography (SiO₂, 5% Et₂O/hexane) afforded vinyl sulfide **9e** (185 mg, 53%) as a white solid; *R*_f = 0.14 (5% Et₂O/hexane); mp = 55–57 °C; IR (film)/cm⁻¹ 2959, 2870, 1722, 1595, 1487, 1401, 1364, 1241, 1178, 1107, 939, 827; ¹H NMR (400 MHz, CDCl₃) δ 7.45–7.37 (m, 2H), 7.19–7.11 (m, 2H), 6.71 (d, *J* = 15.5 Hz, 1H), 6.43 (d, *J* = 15.6 Hz, 1H), 4.11 (t, *J* = 6.7 Hz, 2H), 3.07 (t, *J* = 7.3 Hz, 2H), 2.71 (t, *J* = 7.3 Hz, 2H), 1.66–1.58 (m, 2H), 1.46–1.31 (m, 2H), 0.93 (t, *J* = 7.4 Hz, 3H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 171.6, 135.7, 131.7 (2 × C), 127.0 (2 × C), 126.6, 125.1,

120.7, 64.8, 34.6, 30.6, 27.6, 19.1, 13.7; HRMS (APCI)⁺ *m/z*: calcd for C₁₅H₂₀O₂SBr⁺ [M + H]⁺, 343.0362; found, 343.0371.

tert-Butyl (*S,E*)-(tert-butoxycarbonyl)(5-phenyl-1-(phenylthio)pent-1-en-3-yl)carbamate (**9f**). The title compound was prepared according to an adaptation of General Procedure F, increasing the reaction time to 72 h and employing RhCl(PPh₃)₃ (73 mg, 0.08 mmol), *tert*-butyl (*S*)-(tert-butoxycarbonyl)(5-phenylpent-1-yn-3-yl)-carbamate^{13e} (950 mg, 2.65 mmol), and thiophenol (301 μL, 2.94 mmol). Purification by flash column chromatography (SiO₂, 5% EtOAc/hexane) afforded vinyl sulfide **9f** (1.22 g, 98%) as a colorless oil; *R*_f = 0.75 (10% EtOAc/hexane); IR (film)/cm⁻¹ 2978, 1737, 1799, 1342, 1244, 1140, 1114; ¹H NMR (400 MHz, CDCl₃) δ 7.35–7.27 (m, 5H), 7.26–7.13 (m, 5H), 6.36 (dd, *J* = 15.2, 0.9 Hz, 1H), 6.06 (dd, *J* = 15.2, 7.6 Hz, 1H), 4.76 (q, *J* = 7.4 Hz, 1H), 2.62 (t, *J* = 8.1 Hz, 2H), 2.29–2.14 (m, 1H), 2.14–1.95 (m, 1H), 1.49 (s, 18H). Analytical data are in agreement with those reported in the literature.⁵⁹

(*E*)-Imino(phenyl)(2-(trimethylsilyl)vinyl)-λ⁶-sulfanone (**10a**). The title compound was prepared according to General Procedure A employing vinyl sulfide **9a** (179 mg, 0.86 mmol). Purification by flash column chromatography (KP-Sil, 0% grading to 100% EtOAc/hexane, product eluted at 38% EtOAc) afforded sulfoximine **10a** (107 mg, 52%) as a colorless oil; *R*_f = 0.40 (50% EtOAc/hexane); IR (film)/cm⁻¹ 2957, 2905, 1504, 1450, 1266, 1213, 978, 841, 789; ¹H NMR (400 MHz, CDCl₃) δ 8.02–7.89 (m, 2H), 7.64–7.43 (m, 3H), 7.15 (d, *J* = 17.6 Hz, 1H), 6.69 (d, *J* = 17.6 Hz, 1H), 0.11 (s, 9H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 143.9, 143.4, 142.2, 132.9, 129.3 (2 × C), 128.3 (2 × C), -1.8 (9 × C); HRMS (ESI-TOF) *m/z*: calcd for C₁₁H₁₈NOSSi⁺ [M + H]⁺, 240.0873; found, 240.0871.

(*E*)-Benzyl(imino)(2-(trimethylsilyl)vinyl)-λ⁶-sulfanone (**10b**). The title compound was prepared according to General Procedure A employing vinyl sulfide **9b** (205 mg, 0.92 mmol). Purification by flash column chromatography (SiO₂, 50% EtOAc/hexane) afforded sulfoximine **10b** (178 mg, 76%) as a colorless oil; *R*_f = 0.34 (50% EtOAc/hexane); IR (film)/cm⁻¹ 2955, 1494, 1453, 1248, 1215, 976, 842; ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.32 (m, 5H), 7.05 (d, *J* = 17.8 Hz, 1H), 6.62 (d, *J* = 17.8 Hz, 1H), 4.30 (d, *J* = 13.2 Hz, 1H), 4.20 (d, *J* = 13.2 Hz, 1H), 2.63 (s, 1H), 0.14 (s, 9H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 148.0, 140.7, 130.9, 128.6, 128.5 (2 × C), 128.3, 62.7, -2.1 (9 × C); HRMS (ESI-TOF) *m/z*: calcd for C₁₂H₂₀NOSSi⁺ [M + H]⁺, 254.1035; found, 254.1027.

(*E*)-Imino(4-methoxystyryl)(naphthalen-2-yl)-λ⁶-sulfanone (**10c**). The title compound was prepared according to General Procedure A employing vinyl sulfide **9c** (197 mg, 0.67 mmol). Purification by flash column chromatography (SiO₂, 50% EtOAc/hexane) afforded sulfoximine **10c** (145 mg, 67%) as a colorless oil; *R*_f = 0.24 (50% EtOAc/hexane); IR (film)/cm⁻¹ 3268, 3056, 2840, 1602, 1509, 1256, 1215, 1174, 1066, 976, 864, 813, 757; ¹H NMR (400 MHz, CDCl₃) δ 8.64–8.60 (m, 1H), 8.02–7.94 (m, 3H), 7.92–7.89 (m, 1H), 7.67–7.59 (m, 3H), 7.46–7.41 (m, 2H), 6.91–6.83 (m, 3H), 3.83 (s, 3H), 3.01 (s, 1H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 161.8, 141.5, 140.1, 134.8, 132.4, 130.2 (2 × C), 129.4, 129.3, 128.9, 128.8, 127.8, 127.4, 126.5, 125.3, 123.1, 114.4 (2 × C), 55.4; HRMS (APCI)⁺ *m/z*: calcd for C₁₉H₁₈NO₂S⁺ [M + H]⁺, 324.1053; found, 324.1046.

(*E*)-(4-Bromophenyl)(imino)(styryl)-λ⁶-sulfanone (**10d**). The title compound was prepared according to General Procedure A employing vinyl sulfide **9d** (291 mg, 1.0 mmol). Purification by flash column chromatography (SiO₂, 30% EtOAc/hexane) afforded sulfoximine **10d** (263 mg, 82%) as a yellow oil; *R*_f = 0.38 (30% EtOAc/hexane); IR (film)/cm⁻¹ 3257, 3056, 1729, 1613, 1572, 1464, 1386, 1237, 965, 790; ¹H NMR (400 MHz, CDCl₃) δ 7.94–7.85 (m, 2H), 7.70–7.60 (m, 3H), 7.51–7.45 (m, 2H), 7.44–7.34 (m, 3H), 6.91 (dd, *J* = 15.2, 1.0 Hz, 1H), 2.98 (s, 1H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 142.1, 142.0, 132.4 (3 × C), 131.0, 129.5 (2 × C), 129.0 (2 × C), 129.0, 128.5 (2 × C), 128.0; HRMS (APCI)⁺ *m/z*: calcd for C₁₄H₁₃NOSBr⁺ [M + H]⁺, 321.9901; found, 321.9895.

Butyl (*E*)-3-(2-(4-Bromophenyl)vinylsulfonimidoyl)propanoate (**10e**). The title compound was prepared according to General Procedure A employing vinyl sulfide **9e** (96 mg, 0.28 mmol). Purification by flash column chromatography (SiO₂, 50% EtOAc/

hexane) afforded sulfoximine **10e** (84 mg, 80%) as a white solid; R_f = 0.23 (50% EtOAc/hexane); mp = 57–59 °C; IR (film)/ cm^{-1} 3280, 2959, 2870, 1729, 1617, 1487, 1244, 1211, 1185, 1069, 1006, 857, 801; ^1H NMR (400 MHz, CDCl_3) δ 7.59–7.52 (m, 2H), 7.47 (d, J = 15.3 Hz, 1H), 7.41–7.33 (m, 2H), 6.89 (d, J = 15.3 Hz, 1H), 4.04 (t, J = 6.7 Hz, 2H), 3.46 (td, J = 7.4, 1.7 Hz, 2H), 2.84 (td, J = 7.2, 2.2 Hz, 2H), 2.73 (s, 1H), 1.61–1.48 (m, 2H), 1.39–1.24 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 170.5, 142.6, 132.4 (2 \times C), 131.3, 129.8 (2 \times C), 128.1, 125.6, 65.2, 51.6, 30.4, 28.4, 19.0, 13.6; HRMS (APCI⁺) m/z : calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_3\text{SBr}^+ [\text{M} + \text{H}]^+$, 374.0420; found, 374.0437.

tert-Butyl (tert-Butoxycarbonyl)((3*S*,*E*)-5-phenyl-1-(phenylsulfonylimidoyl)pent-1-en-3-yl)carbamate (10f). The title compound was prepared according to General Procedure A employing vinyl sulfide **9f** (87 mg, 0.18 mmol). Purification by flash column chromatography (KP-Sil, 0% grading to 10% MeOH/ CHCl_3 , eluted at 8% MeOH) afforded sulfoximine **10f** (55 mg, 91%) as a colorless oil in a 1:1 mixture of diastereoisomers; R_f = 0.60 (5% MeOH/ CHCl_3); IR (film)/ cm^{-1} 2978, 1740, 1703, 1368, 1233, 1140; ^1H NMR (400 MHz, CDCl_3) δ 8.02–7.93 (m, 2H), 7.63–7.48 (m, 3H), 7.25–7.11 (m, 5H), 7.05 (dd, J = 15.1, 5.1 Hz, 1H), 6.45 (dd, J = 15.1, 2.9 Hz, 1H), 5.02–4.89 (m, 1H), 2.88 (s, 1H), 2.70–2.55 (m, 2H), 2.37–2.20 (m, 1H), 2.16–2.00 (m, 1H), 1.45 (s, 9H), 1.45 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 152.3 (2 \times C), 144.6, 144.6, 142.5, 140.8, 132.9 (2 \times C), 129.3 (2 \times C), 128.6 (2 \times C), 128.4 (2 \times C), 128.0 (2 \times C), 126.3, 83.2 (2 \times C), 55.8, 34.0, 33.8, 32.4, 28.0 (6 \times C); HRMS (ESI-TOF) m/z : calcd for $\text{C}_{27}\text{H}_{37}\text{N}_2\text{O}_5\text{S}^+ [\text{M} + \text{H}]^+$, 501.2423; found, 501.2434.

(*S*,*E*)-3-Amino-5-phenylpent-1-en-1-yl(imino)(phenyl)- λ^6 -sulfanone (10g). Trifluoroacetic acid (1.1 mL) was added dropwise to a solution of sulfoximine **10f** (194 mg, 0.39 mmol) in CH_2Cl_2 (3.8 mL) at 0 °C, and the reaction was stirred for 3 h. The solvent was then removed under reduced pressure. The crude was dissolved in 20 mL of CH_2Cl_2 and washed with sat. aq. NaHCO_3 (3 \times 20 mL). The solvent was removed under reduced pressure, and purification by flash column chromatography (KP-Sil, 0% grading to 10% MeOH/ CHCl_3 , eluted at 5% MeOH) afforded sulfoximine **10g** (89 mg, 76%) as a yellow oil in a 1:1 mixture of diastereoisomers; R_f = 0.50 (10% MeOH/ CH_2Cl_2); IR (film)/ cm^{-1} 3273, 3027, 2922, 1602, 1446, 1222, 1088, 969, 749, 685; ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, J = 7.2 Hz, 2H), 7.60–7.47 (m, 3H), 7.29–7.22 (m, 2H), 7.20–7.08 (m, 3H), 6.90 (dd, J = 14.8, 5.8 Hz, 1H), 6.53 (d, J = 14.9 Hz, 1H), 3.55–3.44 (m, 1H), 2.70–2.61 (m, 2H), 2.44 (s, 1H), 1.90–1.70 (m, 2H), 1.39 (s, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 148.9, 148.8, 142.9, 141.1, 141.1, 132.9, 131.7, 129.3 (2 \times C), 128.6 (2 \times C), 128.4 (2 \times C), 128.0 (2 \times C), 126.2, 51.6, 38.4, 38.3, 32.1; HRMS (APCI⁺) m/z : calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2\text{OS}^+ [\text{M} + \text{H}]^+$, 301.1369; found, 301.1377.

(2-Hydroxyethyl)(imino)(phenyl)- λ^6 -sulfanone (12a). The title compound was prepared according to General Procedure A employing sulfide **11a** (135 μL , 1.0 mmol) in MeOH (2.0 mL) at 25 °C. After 3 h, the solvent was removed under reduced pressure. Purification by flash column chromatography (SiO_2 , 50% acetone/pentane) afforded sulfoximine **12a** (136 mg, 73%) as a colorless oil; R_f = 0.29 (50% acetone/pentane); IR (film)/ cm^{-1} 3261, 1446, 1215, 1095, 1059, 987, 760, 723, 699; ^1H NMR (400 MHz, CDCl_3) δ 8.04–7.98 (m, 2H), 7.71–7.64 (m, 1H), 7.64–7.57 (m, 2H), 4.70 (t, J = 6.1 Hz, 1H), 4.08 (ddd, J = 12.6, 6.5, 3.8 Hz, 1H), 3.90–3.78 (m, 1H), 3.32 (dt, J = 6.1, 2.9 Hz, 2H), 2.88 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 141.8, 133.6, 129.4 (2 \times C), 128.3 (2 \times C), 58.2, 56.4. Analytical data are in agreement with those reported in the literature.^{31b}

2-Hydroxyethyl(imino)(4-nitrophenyl)- λ^6 -sulfanone (12b). The title compound was prepared according to General Procedure A employing sulfide **11b** (199 mg, 1.0 mmol). Purification by flash column chromatography (SiO_2 , 1–5% MeOH/ CH_2Cl_2) afforded sulfoximine **12b** (201 mg, 87%) as a white solid; R_f = 0.15 (4% MeOH/ CH_2Cl_2); mp = 131–133 °C; IR (film)/ cm^{-1} 3571, 3381, 3153, 3104, 2960, 1633, 1607, 1521, 1469, 1431, 1349, 1308, 1215, 1141, 1088, 1029, 992, 947, 857, 731; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.39 (d, J = 8.9 Hz, 2H), 8.15 (d, J = 8.9 Hz, 2H), 3.68 (t, J =

6.2 Hz, 2H), 3.41 (t, J = 6.2 Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, $\text{DMSO}-d_6$) δ 149.9, 148.6, 129.9 (2 \times C), 124.1 (2 \times C), 58.8, 55.7; HRMS (APCI⁺) m/z : calcd for $\text{C}_8\text{H}_{11}\text{N}_2\text{O}_4\text{S}^+ [\text{M} + \text{H}]^+$, 231.0434; found, 231.0433.

Benzo[d]thiazol-2-yl(2-hydroxyethyl)(imino)- λ^6 -sulfanone (12c). The title compound was prepared according to General Procedure A employing sulfide **11c** (211 mg, 1.0 mmol). Purification by flash column chromatography (SiO_2 , 40% acetone/pentane) afforded sulfoximine **12c** (131 mg, 54%) as a white solid; R_f = 0.24 (40% acetone/pentane); mp = 125–127 °C; IR (film)/ cm^{-1} 3283, 1468, 1315, 1241, 1212, 1051, 980, 764; ^1H NMR (400 MHz, CDCl_3) δ 8.27–8.18 (m, 1H), 8.07–7.98 (m, 1H), 7.69–7.56 (m, 2H), 4.23–4.09 (m, 3H), 3.79–3.68 (m, 1H), 3.66–3.60 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 169.2, 152.7, 137.5, 127.9, 127.7, 125.4, 122.3, 57.8, 56.6; HRMS (APCI⁺) m/z : calcd for $\text{C}_9\text{H}_{11}\text{N}_2\text{O}_2\text{S}_2^+ [\text{M} + \text{H}]^+$, 243.0256; found, 243.0260.

Benzyl(2-hydroxyethyl)(imino)- λ^6 -sulfanone (12d). The title compound was prepared according to General Procedure A employing sulfide **11d** (0.15 mL, 1.0 mmol). Purification by flash column chromatography (SiO_2 , 1–5% MeOH/ CH_2Cl_2) afforded sulfoximine **12d** (180 mg, 91%) as a white solid; R_f = 0.10 (4% MeOH/ CH_2Cl_2); mp = 94–96 °C; IR (film)/ cm^{-1} 3258, 3202 (broad), 2989, 2904, 2855, 1495, 1387, 1342, 1275, 1234, 1208, 1167, 1118, 1081, 1029, 998, 876, 835, 723, 693; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 6.97–6.82 (m, 5H), 4.61 (t, J = 5.2 Hz, 1H), 3.88 (s, 2H), 3.16 (s, 1H), 2.85 (s, 2H), 2.01 (q, J = 1.8 Hz, 2H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 131.1 (2 \times C), 130.4, 128.3 (2 \times C), 128.0, 61.6, 55.6, 54.3; HRMS (APCI⁺) m/z : calcd for $\text{C}_9\text{H}_{14}\text{NO}_2\text{S}^+ [\text{M} + \text{H}]^+$, 200.0740; found, 200.0738.

Imino(phenyl)(vinyl)- λ^6 -sulfanone (13a) and *N*-(Oxo(phenyl)(vinyl)- λ^6 -sulfaneylidene)methanesulfonamide (14a). The title compounds were prepared according to General Procedure G employing sulfoximine **12a** (141 mg, 0.76 mmol). Purification by flash column chromatography (SiO_2 , 50% EtOAc/pentane) afforded vinyl sulfoximine **13a** (63 mg, 50%) and mesylated vinyl sulfoximine **14a** (11 mg, 6%), both as colorless oils. Analytical data for vinyl sulfoximine **13a**: R_f = 0.23 (50% EtOAc/pentane); IR (film)/ cm^{-1} 3269, 3064, 1446, 1223, 1129, 977, 731, 693; ^1H NMR (400 MHz, CDCl_3) δ 8.04–7.94 (m, 2H), 7.67–7.58 (m, 1H), 7.57–7.51 (m, 2H), 6.75 (dd, J = 16.4, 9.5 Hz, 1H), 6.43 (dd, J = 16.4, 0.6 Hz, 1H), 5.99 (dd, J = 9.5, 0.5 Hz, 1H), 2.88 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 141.7, 140.5, 133.0, 129.2 (2 \times C), 128.1 (2 \times C), 126.6. Analytical data are in agreement with those reported in the literature.³⁰ Analytical data for mesylated vinyl sulfoximine **14a**: R_f = 0.29 (50% EtOAc/pentane); IR (film)/ cm^{-1} 3269, 3060, 1308, 1230, 1140, 1099, 1066, 969, 801, 745; ^1H NMR (400 MHz, CDCl_3) δ 8.07–7.96 (m, 2H), 7.76–7.67 (m, 1H), 7.67–7.57 (m, 2H), 6.83 (dd, J = 16.3, 9.6 Hz, 1H), 6.52 (dd, J = 16.3, 1.3 Hz, 1H), 6.23 (dd, J = 9.6, 1.4 Hz, 1H), 3.18 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 137.5, 137.0, 134.5, 129.7 (2 \times C), 129.4, 128.0 (2 \times C), 45.4. Analytical data are in agreement with those reported in the literature.⁶²

Imino(4-nitrophenyl)(vinyl)- λ^6 -sulfanone (13b). The title compound was prepared according to General Procedure G employing sulfoximine **12b** (57.5 mg, 0.25 mmol). Purification by flash column chromatography (SiO_2 , 0–10% Et₂O/ CH_2Cl_2) afforded vinyl sulfoximine **13b** (26.5 mg, 52%) as an off-white solid; R_f = 0.35 (10% Et₂O/ CH_2Cl_2); mp = 95–97 °C; IR (film)/ cm^{-1} 3280, 3105, 3064, 1607, 1528, 1349, 1312, 1230, 1174, 1141, 977, 857, 738, 705; ^1H NMR (400 MHz, CDCl_3) δ 8.51–8.21 (m, 2H), 8.25–8.09 (m, 2H), 6.75 (dd, J = 16.3, 9.5 Hz, 1H), 6.53 (dd, J = 16.3, 0.7 Hz, 1H), 6.12 (dd, J = 9.4, 0.7 Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 150.6, 148.1, 139.7, 129.6 (2 \times C), 129.0, 124.5 (2 \times C); HRMS (ESI-TOF) m/z : calcd for $\text{C}_8\text{H}_9\text{N}_2\text{O}_3\text{S}^+ [\text{M} + \text{H}]^+$, 213.0334; found, 213.0339.

Benzo[d]thiazol-2-yl(imino)(vinyl)- λ^6 -sulfanone (13c). The title compound was prepared according to General Procedure G employing sulfoximine **12c** (133 mg, 0.55 mmol). Purification by flash column chromatography (SiO_2 , 30% acetone/pentane) afforded vinyl sulfoximine **13c** (48 mg, 39%) as a white solid; R_f = 0.39 (30%

acetone/pentane); mp = 99–101 °C; IR (film)/cm⁻¹ 3261, 1468, 1315, 1259, 1237, 1111, 977, 760, 723; ¹H NMR (400 MHz, CDCl₃) δ 8.24–8.17 (m, 1H), 8.02–7.95 (m, 1H), 7.66–7.53 (m, 2H), 7.02 (dd, *J* = 16.4, 9.5 Hz, 1H), 6.71 (dd, *J* = 16.4, 1.0 Hz, 1H), 6.28 (dt, *J* = 9.5, 0.9 Hz, 1H), 3.56 (s, 1H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 169.5, 153.0, 137.7, 137.5, 131.0, 127.7, 127.4, 125.3, 122.2; HRMS (APCI⁺) *m/z*: calcd for C₉H₉N₂OS₂⁺ [M + H]⁺, 225.0151; found, 225.0153.

Benzyl(imino)(vinyl)-λ⁶-sulfanone (13d) and N-(Benzyl(oxo)(vinyl)-λ⁶-sulfaneylidene)methanesulfonamide (14d). The title compounds were prepared according to General Procedure G employing sulfoximine 12d (70 mg, 0.35 mmol). Purification by flash column chromatography (KP-Sil, 0% grading to 50% acetone in pentane) afforded vinyl sulfoximine 13d (22 mg, 35%) as a colorless oil and mesylated vinyl sulfoximine 14d (26 mg, 29%) as a white solid. Analytical data for vinyl sulfoximine 13d: *R_f* = 0.30 (50% EtOAc/pentane); IR (film)/cm⁻¹ 3273, 1215, 967, 701; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.42–7.25 (m, 5H), 6.76 (dd, *J* = 16.4, 9.6 Hz, 1H), 6.07–5.92 (m, 2H), 4.34 (s, 2H), 3.93 (br s, 1H); ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 138.9, 131.0 (2 × C), 130.0, 128.1, 128.0, 127.7, 61.4; HRMS (ESI-TOF) *m/z*: calcd for C₉H₁₂NOS⁺ [M + H]⁺, 182.0640; found, 182.0640. Analytical data for mesylated vinyl sulfoximine 14d: *R_f* = 0.40 (10% Et₂O/CH₂Cl₂); mp = 139–140 °C; IR (film)/cm⁻¹ 3109, 3070, 2982, 2933, 1744, 1532, 1495, 1457, 1409, 1383, 1305, 1230, 1137, 1066, 969, 897, 783, 746, 701; ¹H NMR (400 MHz, CDCl₃) δ 7.41–7.38 (m, 5H), 6.53 (dd, *J* = 16.3, 9.7 Hz), 6.36–6.24 (m, 2H), 4.73 (s, 2H), 3.14 (s, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 133.4, 133.2, 131.7 (2 × C), 129.9, 129.2 (2 × C), 126.3, 62.3, 45.4; HRMS (APCI⁺) *m/z*: calcd for C₁₀H₁₄NO₃S₂⁺ [M + H]⁺, 260.0415; found, 260.0408.

Terminal Vinyl Sulfonylimidamides 18a–d. 1,2-Bis(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)disulfane (16). Pyridinium *p*-toluenesulfonate (2.00 g, 7.90 mmol) was added to a solution of 2-hydroxyethyl disulfide (10.0 mL, 81.7 mmol) and 3,4-dihydropyran (30.0 mL, 328 mmol) in CH₂Cl₂ (100 mL) at 0 °C. The solution was allowed to warm to room temperature and was stirred for 18 h. The solvent was removed in vacuo and the crude residue was purified by flash column chromatography (KP-Sil, 0% grading to 50% Et₂O in pentane, eluted at 10%), which afforded disulfide 16 (22.7 g, 86%) as a colorless oil; *R_f* = 0.44 (25% Et₂O in pentane); IR (film)/cm⁻¹ 3008, 2941, 2870, 1438, 1349, 1200, 1118, 1077, 1025, 753; ¹H NMR (400 MHz, CDCl₃) δ 4.64 (dd, *J* = 4.2, 2.9 Hz, 2H), 4.04–3.92 (m, 2H), 3.88 (ddd, *J* = 11.2, 8.0, 3.5 Hz, 2H), 3.69 (dt, *J* = 10.4, 6.7 Hz, 2H), 3.58–3.47 (m, 2H), 3.01–2.85 (m, 4H), 1.89–1.66 (m, 4H), 1.65–1.46 (m, 8H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 99.1 (2 × C), 66.1 (2 × C), 62.4 (2 × C), 39.2 (2 × C), 30.7 (2 × C), 25.6 (2 × C), 19.5 (2 × C); HRMS (APCI⁺) *m/z*: calcd for C₁₄H₂₆O₄S₂⁺ [M]⁺, 322.1267; found, 322.1276.

4-Phenyl-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethylsulfonimidoyl)piperidine (17a). The title compound was prepared according to General Procedure H employing silver nitrate (603 mg, 4.0 mmol), triethylamine (554 μL, 4.0 mmol), disulfide 16 (644 mg, 2.0 mmol), and 4-phenyl piperidine (427 mg, 2.66 mmol) in MeOH (26 mL) followed by ammonium carbamate (223 mg, 2.86 mmol), iodosylbenzene (788 mg, 3.58 mmol), and acetic acid (80 μL, 1.4 mmol) in *i*PrOH (7 mL). Purification by flash column chromatography (KP-Sil, 50% grading to 100% EtOAc in pentane, product eluted at 100%) afforded sulfonimidamide 17a (400 mg, 57% over two steps, dr 1:1) as a colorless oil; *R_f* = 0.40 (100% EtOAc); IR (film)/cm⁻¹ 3280, 2937, 2847, 1244, 1118, 1028, 931; ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.27 (m, 2H), 7.25–7.14 (m, 3H), 4.71–4.57 (m, 1H), 4.24–4.09 (m, 1H), 4.09–3.96 (m, 2H), 3.96–3.81 (m, 2H), 3.60–3.48 (m, 1H), 3.40–3.16 (m, 2H), 2.93–2.75 (m, 2H), 2.57 (td, *J* = 12.1, 3.0 Hz, 1H), 2.28 (d, *J* = 7.8 Hz, 1H), 2.03–1.88 (m, 2H), 1.88–1.64 (m, 5H), 1.64–1.43 (m, 4H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 145.3, 128.8, 126.9, 126.7, 99.6, 99.5, 62.8, 62.0, 61.8, 50.1, 50.0, 47.5, 47.5, 47.2, 47.1, 42.5, 33.8, 33.6, 33.5, 30.8, 30.7, 25.4, 19.8; HRMS (ESI-TOF) *m/z*: calcd for C₁₈H₂₉N₂O₃S⁺ [M + H]⁺, 353.1899; found, 353.1901.

4-Methyl-2-phenyl-1-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethylsulfonimidoyl)piperazine (17b). The title compound was prepared according to General Procedure H employing 1-methyl-3-phenylpiperazine (587 mg, 3.3 mmol), triethylamine (693 μL, 5.0 mmol), silver nitrate (849 mg, 5.0 mmol), and disulfide 16 (806 mg, 2.5 mmol) in MeOH (25 mL) followed by ammonium carbamate (390 mg, 5.0 mmol), iodosylbenzene (1.37 g, 6.25 mmol), and acetic acid (143 μL, 2.5 mmol) in *i*PrOH (13 mL). Purification by flash column chromatography (SiO₂, 70% EtOAc in pentane) afforded sulfonimidamide 17b (292 mg, 32% over two steps) as a complex mixture of diastereomers as a brown oil; *R_f* = 0.11 (70% EtOAc in pentane); IR (film)/cm⁻¹ 3272, 2937, 2870, 2791, 1453, 1244, 1148, 1118, 1029, 976, 917; ¹H NMR (400 MHz, CDCl₃) δ 7.71–7.64 (m, 4H), 7.38–7.32 (m, 4H), 7.31–7.27 (m, 2H), 5.14 (d, *J* = 3.4 Hz, 1H), 5.10 (d, *J* = 4.3 Hz, 1H), 4.60–4.53 (m, 2H), 4.13–4.01 (m, 2H), 3.89–3.74 (m, 6H), 3.54–3.45 (m, 2H), 3.41–3.05 (m, 6H), 2.98–2.78 (m, 4H), 2.52–2.47 (m, 2H), 2.31–2.28 (m, 6H), 2.30 (s, 2H), 2.22–2.11 (m, 2H), 1.84–1.64 (m, 4H), 1.64–1.45 (m, 8H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 139.7, 128.5, 128.4, 128.3, 128.13, 128.10, 127.5, 127.4, 99.1, 99.0, 62.3, 62.2, 61.93, 61.89, 59.1, 58.5, 56.2, 55.9, 55.4, 55.2, 53.64, 53.63, 46.30, 46.27, 42.1, 41.9, 30.4, 30.3, 25.2, 19.32, 19.29; HRMS (ESI-TOF) *m/z*: calcd for C₁₈H₃₀N₃O₃S⁺ [M + H]⁺, 368.2008; found, 368.2006.

N-(3-(10,11-Dihydro-5H-dibenzo[*a,d*]annulen-5-ylidene)propyl)-N-methyl-2-((tetrahydro-2H-pyran-2-yl)oxy)ethane-1-sulfonimidamide (17c). The title compound was prepared according to General Procedure H employing nortriptyline hydrochloride (1.00 g, 3.33 mmol), triethylamine (1.20 mL, 8.75 mmol), silver nitrate (849 mg, 5.0 mmol), and disulfide 16 (806 mg, 2.5 mmol) in MeOH (25 mL) followed by ammonium carbamate (390 mg, 5.0 mmol), iodosylbenzene (1.37 g, 6.25 mmol), and acetic acid (143 μL, 2.5 mmol) in *i*PrOH (13 mL). Purification by flash column chromatography (SiO₂, 20% acetone in pentane) afforded sulfonimidamide 17c (375 mg, 33% over two steps, dr 1:1) containing a small amount of an unidentified and inseparable impurity as a brown oil; *R_f* = 0.18 (20% acetone in pentane); IR (film)/cm⁻¹ 3309, 3015, 2937, 1643, 1483, 1442, 1244, 1121, 1077, 1028, 969, 766; ¹H NMR (400 MHz, CDCl₃) δ 7.29–7.25 (m, 1H), 7.23–7.13 (m, 6H), 7.06–7.03 (m, 1H), 5.85 (td, *J* = 7.4, 1.4 Hz, 1H), 4.60 (dd, *J* = 4.5, 3.0 Hz, 1H), 4.10 (ddt, *J* = 10.9, 9.3, 6.1 Hz, 1H), 3.90–3.80 (m, 2H), 3.65–3.13 (m, 9H), 2.97 (s, 1H), 2.76 (s, 3H), 2.44–2.34 (m, 2H), 1.83–1.70 (m, 2H), 1.61–1.49 (m, 4H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 145.1, 140.8, 139.7, 139.4, 137.0, 130.1, 128.5, 128.1, 128.0, 127.6, 127.3, 127.2, 126.1, 125.7, 99.2, 62.6, 61.8, 61.6, 50.5, 50.3, 33.7, 32.0, 30.5, 28.6, 25.2, 19.5; HRMS (ESI-TOF) *m/z*: calcd for C₂₆H₃₅N₂O₃S⁺ [M + H]⁺, 455.2368; found, 455.2354.

N-Benzyl-N-methyl-2-((tetrahydro-2H-pyran-2-yl)oxy)ethane-1-sulfonimidamide (17d). The title compound was prepared according to General Procedure H employing silver nitrate (603 mg, 4.0 mmol), triethylamine (554 μL, 4.0 mmol), *N*-methylbenzylamine (346 μL, 2.66 mmol), and disulfide 16 (645.0 mg, 2.0 mmol) in MeOH (20 mL) followed by ammonium carbamate (390 mg, 5.0 mmol), iodosylbenzene (1.37 g, 6.25 mmol), and acetic acid (143 μL, 2.5 mmol) in *i*PrOH (13 mL). Purification by flash column chromatography (KP-Sil 0% grading to 100% MeOH in CH₂Cl₂, product eluted at 7%) afforded sulfonimidamide 17d (324 mg, 52% over two steps, dr 1:1) as a yellow oil; *R_f* = 0.28 (100% EtOAc); IR (film)/cm⁻¹ 3280, 2937, 2870, 1454, 1349, 1245, 1122, 1077, 1028, 976, 731; ¹H NMR (400 MHz, CDCl₃) δ 7.30–7.27 (m, 5H), 4.65 (m, 1H), 4.52–4.32 (m, 2H), 4.24–4.10 (m, 1H), 3.97–3.84 (m, 2H), 3.58–3.50 (m, 1H), 3.47–3.25 (m, 2H), 2.81 (d, *J* = 3.2 Hz, 3H), 2.34 (d, *J* = 8.3 Hz, 1H), 1.92–1.71 (m, 2H), 1.66–1.47 (m, 4H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 137.0, 128.8, 128.1, 127.8, 99.5, 62.8, 62.0, 61.8, 54.9, 50.9, 35.4, 30.8, 25.4, 19.8; HRMS (ESI-TOF) *m/z*: calcd for C₁₅H₂₅N₂O₃S⁺ [M + H]⁺, 313.1580; found, 313.1578.

4-Phenyl-1-(vinylsulfonimidoyl)piperidine (18a). The title compound was prepared according to General Procedure I employing sulfonimidamide 17a (32 mg, 0.09 mmol). Purification by flash column chromatography (KP-Sil, 50% grading to 100% EtOAc in

pentane, product eluted at 100%) afforded sulfonimidamide **18a** (17 mg, 70% over two steps) as a colorless oil; $R_f = 0.50$ (100% EtOAc); IR (film)/ cm^{-1} 3287, 2937, 1244, 1051, 924, 734; ^1H NMR (400 MHz, CDCl_3) δ 7.37–7.27 (m, 2H), 7.25–7.13 (m, 3H), 6.52 (dd, $J = 16.6, 9.9$ Hz, 1H), 6.26 (d, $J = 16.6$ Hz, 1H), 6.03 (d, $J = 9.9$ Hz, 1H), 4.02 (ddt, $J = 11.9, 4.4, 2.5$ Hz, 1H), 3.92 (ddt, $J = 11.9, 4.6, 2.4$ Hz, 1H), 2.72–2.44 (m, 3H), 2.37 (s, 1H), 2.01–1.87 (m, 2H), 1.87–1.72 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 145.2, 133.4, 128.7 (2 \times C), 127.7, 126.9 (2 \times C), 126.7, 47.8, 47.4, 42.3, 33.4, 33.1; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{13}\text{H}_{19}\text{N}_2\text{OS}^+ [\text{M} + \text{H}]^+$, 251.1218; found, 251.1207.

4-Methyl-2-phenyl-1-(vinylsulfonimidoyl)piperazine (18b). The title compound was prepared according to General Procedure I employing sulfonimidamide **17b** (238 mg, 0.65 mmol). Purification by flash column chromatography (SiO_2 , 20% acetone in pentane) afforded sulfonimidamide **18b** (70 mg, 42% over two steps, dr 1:2) as a brown oil; $R_f = 0.27$ (20% acetone in pentane); IR (film)/ cm^{-1} 3272, 2937, 2795, 1453, 1267, 1244, 1148, 973, 924; ^1H NMR (400 MHz, CDCl_3) δ 7.69 (dd, $J = 7.3, 1.9$ Hz, 2H), 7.63 (dd, $J = 7.4, 1.8$ Hz, 2H), 7.36–7.32 (m, 4H), 7.31–7.25 (m, 2H), 6.27–6.09 (m, 4H), 5.76–5.71 (m, 2H), 5.05–5.02 (m, 2H), 3.72–3.67 (m, 2H), 3.35–3.13 (m, 4H), 2.84–2.77 (m, 2H), 2.51–2.47 (m, 2H), 2.33 (s, 2H), 2.30–2.17 (m, 6H), 2.24–2.13 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 139.6, 137.1, 136.4, 128.6, 128.4, 128.3, 128.2, 127.5, 125.3, 125.0, 58.8, 57.9, 56.3, 56.2, 54.9, 54.8, 46.3, 42.1, 41.9; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{13}\text{H}_{20}\text{N}_3\text{OS}^+ [\text{M} + \text{H}]^+$, 266.1327; found, 266.1334.

N-(3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)-N-methylethanesulfonimidamide (18c). The title compound was prepared according to General Procedure I employing sulfonimidamide **17c** (516 mg, 1.13 mmol). Purification by flash column chromatography (SiO_2 , 50% EtOAc in pentane) afforded sulfonimidamide **18c** (188 mg, 47%) as a brown oil; $R_f = 0.33$ (50% EtOAc in pentane); IR (film)/ cm^{-1} 3309, 3060, 3015, 2914, 1483, 1453, 1267, 1107, 965, 742; ^1H NMR (400 MHz, CDCl_3) δ 7.29–7.27 (m, 1H), 7.26–7.09 (m, 6H), 7.08–7.02 (m, 1H), 6.42 (dd, $J = 16.6, 9.8$ Hz, 1H), 6.19 (d, $J = 16.6$ Hz, 1H), 5.90 (d, $J = 9.9$ Hz, 1H), 5.85 (t, $J = 7.5$ Hz, 1H), 3.46–3.23 (m, 3H), 3.17–3.05 (m, 1H), 3.02–2.92 (m, 1H), 2.85–2.75 (m, 1H), 2.71–2.60 (m, 3H), 2.44–2.32 (m, 2H), 2.09 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 145.2, 140.7, 139.7, 139.4, 137.0, 133.4, 130.1, 128.5, 128.1, 128.0, 127.6, 127.23, 127.20, 126.6, 126.1, 125.8, 50.5 (2 \times C), 33.7, 31.9, 28.3; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{21}\text{H}_{25}\text{N}_2\text{OS}^+ [\text{M} + \text{H}]^+$, 353.1688; found, 353.1682.

N-Benzyl-N-methylethanesulfonimidamide (18d). The title compound was prepared according to General Procedure I employing sulfonimidamide **17d** (144 mg, 0.46 mmol). Purification by flash column chromatography (KP-Sil, 30% grading to 100% EtOAc/pentane, eluted at 50%) gave sulfonimidamide **18d** (22 mg, 23% over two steps) as a pale-yellow oil; $R_f = 0.25$ (100% EtOAc); IR (film)/ cm^{-1} 3280, 3030, 1358, 1243, 1102, 969, 733; ^1H NMR (400 MHz, CDCl_3) δ 7.43–7.27 (m, 5H), 6.56 (dd, $J = 16.6, 9.9$ Hz, 1H), 6.31 (d, $J = 16.6$ Hz, 1H), 6.03 (d, $J = 9.9$ Hz, 1H), 4.30 (m, 2H), 2.73 (s, 3H), 2.47 (s, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 136.6, 133.5, 128.8 (2 \times C), 128.3 (2 \times C), 127.9, 127.2, 55.0, 35.3; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{OS}^+ [\text{M} + \text{H}]^+$, 211.0900; found, 211.0896.

N-Propargyl Vinyl Sulfoximines and Sulfonimidamides 19a–g. **Phenyl(prop-2-yn-1-ylimino)(vinyl)- λ^6 -sulfanone (19a).** The title compound was prepared according to General Procedure J employing sulfoximine **11a** (36 mg, 0.21 mmol). Purification by flash column chromatography (KP-Sil, 0% grading to 50% EtOAc/pentane, product eluted at 25%) afforded sulfoximine **19a** (25 mg, 57%) as a colorless oil; $R_f = 0.45$ (50% EtOAc in pentane); IR (film)/ cm^{-1} 3295, 2321, 1446, 1267, 1216, 1131, 971, 742; ^1H NMR (400 MHz, CDCl_3) δ 7.95–7.90 (m, 2H), 7.62–7.51 (m, 3H), 6.68 (dd, $J = 16.5, 9.6$ Hz, 1H), 6.38 (d, $J = 16.5$ Hz, 1H), 6.03 (d, $J = 9.9$ Hz, 1H), 3.87 (dd, $J = 17.2, 2.5$ Hz, 1H), 3.79 (dd, $J = 17.3, 2.5$ Hz, 1H), 2.19 (t, $J = 2.5$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 138.5, 138.4, 133.3, 129.5 (2

\times C), 129.0 (2 \times C), 128.2, 83.0, 70.6, 32.6; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{11}\text{H}_{12}\text{NOS}^+ [\text{M} + \text{H}]^+$, 206.0640; found, 206.0647.

(E)-Phenyl(prop-2-yn-1-ylimino)(styryl)- λ^6 -sulfanone (19b). The title compound was prepared according to General Procedure J employing sulfoximine **5a** (36 mg, 0.15 mmol). Purification by flash chromatography (KP-Sil, 0% grading to 100% EtOAc/hexane, eluted at 35% EtOAc) afforded **19b** (23 mg, 55%) as a dark-orange oil; $R_f = 0.64$ (50% EtOAc/pentane); IR (film)/ cm^{-1} 3295, 3060, 1610, 1446, 1267, 1215, 1133, 1081, 745, 686; ^1H NMR (400 MHz, CDCl_3) δ 8.01–7.98 (m, 2H), 7.62–7.52 (m, 4H), 7.48–7.46 (m, 2H), 7.41–7.36 (m, 3H), 6.89 (d, $J = 15.3$ Hz, 1H), 3.91 (dd, $J = 14.8, 2.5$ Hz, 1H), 3.81 (dd, $J = 14.8, 2.6$ Hz, 1H), 2.23 (t, $J = 2.53$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 142.9, 139.3, 133.0, 132.7, 131.0, 129.4 (2 \times C), 129.0 (2 \times C), 128.6 (2 \times C), 128.5 (2 \times C), 127.2, 83.2, 70.5, 32.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{17}\text{H}_{16}\text{NOS}^+ [\text{M} + \text{H}]^+$, 282.0953; found, 282.0960.

(E)-(2-Cyclohexylvinyl)(phenyl)(prop-2-yn-1-ylimino)- λ^6 -sulfanone (19c). The title compound was prepared according to General Procedure J employing sulfoximine **5b** (40 mg, 0.16 mmol). Purification via flash column chromatography (KP-Sil, 0% grading to 100% EtOAc/petroleum ether, eluted at 35% EtOAc) afforded **19c** (35 mg, 77%) as a clear oil; $R_f = 0.61$ (50% EtOAc/pentane); IR (film)/ cm^{-1} 3295, 2926, 2851, 1446, 1267, 1218, 1133, 969, 752, 689; ^1H NMR (400 MHz, CDCl_3) δ 7.91–7.89 (m, 2H), 7.60–7.56 (m, 1H), 7.54–7.50 (m, 2H), 6.83 (dd, $J = 8.7, 6.3$ Hz, 1H), 6.28 (d, $J = 15.2$ Hz, 1H), 3.81 (dd, $J = 14.7, 2.6$ Hz, 1H), 3.71 (dd, $J = 14.9, 2.5$ Hz, 1H), 2.20 (t, $J = 2.5$ Hz, 1H), 2.18–2.12 (m, 1H), 1.74 (m, 4H), 1.67–1.63 (m, 1H), 1.30–1.09 (m, 5H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 152.1, 139.3, 132.8, 129.3 (2 \times C), 128.6 (2 \times C), 127.8, 83.2, 70.3, 40.0, 32.6, 31.4, 31.2, 25.7, 25.6 (2 \times C); HRMS (ESI-TOF) m/z : calcd for $\text{C}_{17}\text{H}_{22}\text{NOS}^+ [\text{M} + \text{H}]^+$, 288.1422; found, 288.1418.

(E)-Phenyl(prop-2-yn-1-ylimino)(2-(pyridin-2-yl)vinyl)- λ^6 -sulfanone (19d). The title compound was prepared according to General Procedure J employing sulfoximine **5d** (40 mg, 0.16 mmol). Purification by flash column chromatography (KP-Sil, 0% grading to 100% EtOAc/pentane, eluted at 56% EtOAc) afforded **19d** (31 mg, 77%) as a brown oil; $R_f = 0.30$ (50% EtOAc/pentane); IR (film)/ cm^{-1} 3298, 3056, 2926, 1580, 1267, 1215, 1129, 1080, 969, 752, 685; ^1H NMR (400 MHz, CDCl_3) δ 8.60–8.59 (d, $J = 5.5$ Hz, 1H), 8.02–8.00 (m, 2H), 7.73–7.69 (m, 1H), 7.59 (d, $J = 15.1$ Hz, 1H), 7.61–7.57 (m, 1H), 7.56–7.51 (m, 2H), 7.40 (d, $J = 15.0$ Hz, 1H), 7.38 (d, $J = 7.4$ Hz, 1H), 7.28–7.25 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 151.4, 150.2, 141.3, 138.9, 137.0, 133.1, 131.8, 129.4 (2 \times C), 128.8 (2 \times C), 125.1, 124.8, 83.1, 70.5, 32.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{16}\text{H}_{15}\text{N}_2\text{OS}^+ [\text{M} + \text{H}]^+$, 283.0905; found, 283.0920.

4-Phenyl-1-(N-(prop-2-yn-1-yl)vinylsulfonimidoyl)piperidine (19e). The title compound was prepared according to General Procedure J employing sulfonimidamide **18a** (16 mg, 0.07 mmol). Purification by flash column chromatography (KP-Sil, 35% grading to 100% EtOAc in pentane, eluted at 60%) afforded sulfonimidamide **19e** (10 mg, 52%) as a colorless oil; $R_f = 0.70$ (100% EtOAc); IR (film)/ cm^{-1} 3284, 2918, 2844, 1278, 1230, 1140, 924, 756; ^1H NMR (400 MHz, CDCl_3) δ 7.36–7.28 (m, 2H), 7.25–7.16 (m, 3H), 6.52 (dd, $J = 16.7, 9.9$ Hz, 1H), 6.24 (d, $J = 16.8$ Hz, 1H), 6.01 (d, $J = 10.0$ Hz, 1H), 4.12–3.75 (m, 4H), 2.72–2.47 (m, 3H), 2.22 (t, $J = 2.6$ Hz, 1H), 2.02–1.69 (m, 4H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 Hz, CDCl_3) δ 145.2, 132.9, 128.7 (2 \times C), 127.4, 126.9 (2 \times C), 126.7, 83.0, 70.1, 47.6, 47.5, 42.2, 33.1, 33.0, 30.7; HRMS (ESI-TOF) m/z : calcd for $\text{C}_{16}\text{H}_{21}\text{N}_2\text{OS}^+ [\text{M} + \text{H}]^+$, 289.1369; found, 289.1371.

4-Methyl-2-phenyl-1-(N-(prop-2-yn-1-yl)vinylsulfonimidoyl)piperazine (19f). The title compound was prepared according to General Procedure J employing sulfonimidamide **18b** (53 mg, 0.20 mmol, dr 1:2). Purification by flash column chromatography (SiO_2 , 10% acetone in pentane) afforded sulfonimidamide **19f** (29 mg, 48%, dr 1:2) as a brown oil; $R_f = 0.26$ (10% acetone in pentane); IR (film)/ cm^{-1} 3287, 2937, 2844, 2795, 1457, 1278, 1230, 1148, 972, 917, 767; ^1H NMR (400 MHz, CDCl_3) δ 7.77–7.72 (m, 2H), 7.70 (dd, $J = 7.4, 1.8$ Hz, 2H), 7.37–7.24 (m, 6H), 6.29 (dd, $J = 16.5, 9.5$ Hz, 1H), 6.16 (d, $J = 16.5$ Hz, 1H), 6.00 (dd, $J = 16.5, 9.6$ Hz, 1H), 5.89 (d, $J = 16.5$

H_z, 1H), 5.77 (d, *J* = 9.6 Hz, 1H), 5.56 (d, *J* = 9.6 Hz, 1H), 4.98 (d, *J* = 4.2 Hz, 1H), 4.94–4.90 (m, 1H), 3.89–3.85 (m, 4H), 3.66–3.57 (m, 2H), 3.29–3.22 (m, 2H), 3.15 (dt, *J* = 11.9, 1.8 Hz, 1H), 3.10 (dt, *J* = 11.6, 1.8 Hz, 1H), 2.91–2.87 (m, 1H), 2.81–2.77 (m, 1H), 2.56 (dd, *J* = 11.6, 4.5 Hz, 1H), 2.53–2.44 (m, 1H), 2.31–2.27 (m, 8H), 2.21 (t, *J* = 2.5 Hz, 1H), 2.19 (t, *J* = 2.5 Hz, 1H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 139.3, 136.8, 134.3, 129.3, 128.5, 128.2, 128.0, 127.7, 126.1, 124.8, 82.9, 82.6, 70.2, 69.9, 59.2, 57.2, 56.2, 55.9, 54.8, 54.7, 46.2, 41.9, 41.5, 30.8, 30.7; HRMS (ESI-TOF) *m/z*: calcd for C₁₆H₂₂N₃OS⁺ [M + H]⁺, 304.1484; found, 304.1497.

N-(3-(10,11-Dihydro-5H-dibenzo[*a,d*]7[annulen-5-ylidene)propyl)-*N*-methyl-*N'*-(prop-2-yn-1-yl)ethanesulfonimidamide (19g). The title compound was prepared according to General Procedure J employing sulfonimidamide 18c (70 mg, 0.20 mmol). Purification by flash column chromatography (SiO₂, 30% EtOAc in pentane) afforded sulfonimidamide 19g (63 mg, 81%) as a brown oil; *R*_f = 0.53 (50% EtOAc in pentane); IR (film)/cm⁻¹ 3287, 3060, 3019, 2914, 2855, 1483, 1442, 1282, 1230, 1148, 969, 756; ¹H NMR (400 MHz, CDCl₃) δ 7.32–7.25 (m, 1H), 7.26–7.09 (m, 6H), 7.08–7.02 (m, 1H), 6.49–6.38 (m, 1H), 6.15 (d, *J* = 16.7 Hz, 1H), 5.92–5.81 (m, 2H), 3.82 (d, *J* = 2.9 Hz, 2H), 3.51–3.11 (m, 5H), 3.03–2.93 (m, 1H), 2.87–2.74 (m, 1H), 2.69 (s, 3H), 2.41 (qd, *J* = 7.3, 1.4 Hz, 2H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 145.0, 140.8, 139.7, 139.3, 137.0, 133.1, 130.0, 128.5, 128.1, 128.0, 127.6, 127.2 (2 × C), 126.4, 126.1, 125.8, 82.7, 70.0, 50.4 (2 × C), 33.7, 32.0, 30.6, 28.1; HRMS (ESI-TOF) *m/z*: calcd for C₂₄H₂₇N₂OS⁺ [M + H]⁺, 391.1844; found, 391.1854.

Chiral Separation of 10g. Vinyl sulfoximine 10g (68 mg) was dissolved to 12 mg/mL in MeOH and was then purified by HPLC using a Chiralpak IG (20 mm × 250 mm, 5 μm) column. Combined fractions of each isomer were evaporated to dryness to afford 10g-A (12.9 mg, >99% diastereomeric excess (de)) and 10g-B (10.2 mg, 97% de) as yellow oils.

10g-A: IR (film)/cm⁻¹ 3295, 3060, 2926, 1495, 1446, 1222, 753; ¹H NMR (400 MHz, CDCl₃) δ 8.00–7.96 (m, 2H), 7.61–7.52 (m, 3H), 7.28–7.09 (m, 5H), 6.93 (dd, *J* = 14.9, 5.8 Hz, 1H), 6.56 (dd, *J* = 14.9, 1.4 Hz, 1H), 3.60–3.51 (m, 1H), 2.73–2.63 (m, 2H), 2.58 (s, 1H), 1.88–1.77 (m, 2H), 1.66 (s, 2H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 148.7, 142.9, 141.2, 133.0, 131.8, 129.3 (2 × C), 128.7 (2 × C), 128.5 (2 × C), 128.1 (2 × C), 126.3, 51.7, 38.4, 32.2.

10g-B: IR (film)/cm⁻¹ 3306, 3063, 2922, 1495, 1446, 1222, 987, 752; ¹H NMR (400 MHz, CDCl₃) δ 8.01–7.96 (m, 2H), 7.62–7.52 (m, 3H), 7.28–7.10 (m, 5H), 6.93 (dd, *J* = 14.9, 5.8 Hz, 1H), 6.55 (dd, *J* = 14.9, 1.4 Hz, 1H), 3.60–3.47 (m, 1H), 2.74–2.63 (m, 2H), 2.55 (s, 1H), 1.91–1.78 (m, 2H), 1.66 (s, 2H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 148.9, 143.0, 141.1, 133.0, 131.8, 129.4 (2 × C), 128.7 (2 × C), 128.5 (2 × C), 128.1 (2 × C), 126.3, 51.7, 38.5, 32.12.

Chiral Separation of 19f. Vinyl sulfonimidamide 19f (21.8 mg) was dissolved to 10 mg/mL in heptane/EtOH 6:4 and was then purified by HPLC using an Amy-C (20 mm × 250 mm, 5 μm) column. Combined fractions of each isomer were evaporated to dryness to afford 19f-A (2.5 mg, >99% ee, >99% de, [α]_D²¹ = +28 (c 0.003, CHCl₃)), 19f-B (4.4 mg, >99% ee, >99% de, [α]_D²¹ = -37 (c 0.002, CHCl₃)), 19f-C (1.9 mg, 96% ee, >99% de, [α]_D²¹ = +31 (c 0.001, CHCl₃)), and 19f-D (3.6 mg, >99% ee, 97% de, [α]_D²¹ = -28 (c 0.003, CHCl₃)) as clear glassy solids.

Enantiomeric pair 19f-A and 19f-D; IR (film)/cm⁻¹ 3287, 2937, 2795, 1457, 1282, 1140, 972, 917; ¹H NMR (400 MHz, CDCl₃) δ 7.75 (dd, *J* = 8.0, 1.7 Hz, 2H), 7.40–7.27 (m, 3H), 6.00 (dd, *J* = 16.5, 9.6 Hz, 1H), 5.89 (d, *J* = 16.5 Hz, 1H), 5.55 (d, *J* = 9.5 Hz, 1H), 4.91 (d, *J* = 4.3 Hz, 1H), 3.86 (d, *J* = 2.5 Hz, 2H), 3.57 (s, 1H), 3.24 (d, *J* = 3.3 Hz, 1H), 3.09 (d, *J* = 11.6 Hz, 1H), 2.94–2.82 (m, 1H), 2.55 (dd, *J* = 11.7, 4.5 Hz, 1H), 2.28 (s, 3H), 2.27 (m, 1H), 2.19 (t, *J* = 2.5 Hz, 1H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 139.6, 134.6, 129.5, 128.2, 127.8, 126.2, 83.1, 70.1, 59.5, 56.5, 55.0, 46.5, 41.7, 30.9.

Enantiomeric pair 19f-B and 19f-C; IR (film)/cm⁻¹ 3287, 2939, 2795, 1454, 1278, 1230, 1151, 976, 928; ¹H NMR (400 MHz, CDCl₃) δ 7.75–7.62 (m, 2H), 7.38–7.27 (m, 3H), 6.28 (dd, *J* = 16.6, 9.5 Hz, 1H), 6.16 (d, *J* = 16.6 Hz, 1H), 5.76 (d, *J* = 9.5 Hz, 1H), 4.98 (d, *J* = 4.3 Hz, 1H), 3.86 (d, *J* = 2.5 Hz, 2H), 3.71–3.52 (m, 1H),

3.31–3.04 (m, 2H), 2.85–2.71 (m, 1H), 2.45 (dd, *J* = 11.9, 4.4 Hz, 1H), 2.28 (s, 3H), 2.22–2.12 (m, 2H); ¹³C{¹H} NMR (101 Hz, CDCl₃) δ 140.5, 137.1, 128.7, 128.4, 127.6, 124.9, 82.5, 70.4, 57.4, 56.1, 54.9, 46.5, 42.1, 31.0.

Chiral Separation of 19g. Vinyl sulfonimidamide 19g (51.6 mg) was dissolved to 16 mg/mL in 2:1 isopropyl alcohol (IPA)/CH₂Cl₂ and was then purified by HPLC using a Chiralpak IG (20 mm × 250 mm, 5 μm) column. Combined fractions of each enantiomer were evaporated to dryness to afford 19g-A (10.6 mg, 99% ee, [α]_D²¹ = -33 (c 0.01, CHCl₃)) and 19g-B (13.3 mg, 98% ee, [α]_D²¹ = +33 (c 0.01, CHCl₃)) as brown glassy solids.

Computational Methods. All calculations were performed using Gaussian 16.⁶³ Stationary points were confirmed using frequency calculations (default divergence criteria). Conformational searches were carried out as described in the Supporting Information. Electronic circular dichroism spectra were calculated for individual conformers using time-dependent density-functional theory (TDDFT) calculations at cam-B3LYP/6-311++g(d,p) in a continuum solvent (CPCM) acetonitrile for up to 200 states. Copies of Gaussian log files for optimizations and frequency calculations, TDDFT calculations, and tables of ECD data are available from a data depository via the data-set collection DOIs 10.14469/hpc/7859 (sulfoximines) and 10.14469/hpc/7577 (sulfonimidamides) and data sets cited therein.

Electronic Circular Dichroism. The circular dichroism and UV–vis spectra were recorded on a Chirascan spectrometer (Applied Photophysics). A 0.1 cm path-length cuvette was loaded with 200 μL of each compound (50 μM in acetonitrile) or acetonitrile blank. The ellipticity was measured from 340 to 195 nm in 1.0 nm intervals (bandwidth = 2.0 nm) for 1.0 s per measurement. Measurements were taken in duplicate and normalized against the acetonitrile control.

Configurational Assignment by Comparison of the Calculated and Experimental ECD. Comparative analysis was performed using SpecDis.⁵² For each structure/substructure, the computed ECD and UV–vis spectra were summed according to their Boltzmann weighting at 298 K. The relevant experimental ECD and UV–vis spectra were then input and similarity analysis was performed by first aligning the UV spectra (shift range = -30 to +30 nm; bandwidth = 0.1–0.3; energy range = 200–340 nm) and then performing a local refinement to optimize the alignment of the ECD. Assignments were made on the basis of both manual inspection of the ECD alignments and the quantification of the similarity scores.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.1c00373>.

Details of the relative energies and structures of conformers of 10g, 19f, and 19g and full comparisons of the computational and experimental UV and ECD spectra (Figures S1–S7); ¹H and ¹³C NMR spectra for novel compounds; HPLC traces of enantioenriched compounds; and computational data including Tables S1–S7 (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Gregory B. Craven – Molecular Sciences Research Hub, Department of Chemistry, Imperial College London, London W12 0BZ, U.K.; The Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, U.K.; orcid.org/0000-0003-3414-8348; Email: g.craven13@gmail.com

James A. Bull – Molecular Sciences Research Hub, Department of Chemistry, Imperial College London, London W12 0BZ,

U.K.; orcid.org/0000-0003-3993-5818; Email: j.bull@imperial.ac.uk

Alan Armstrong – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.; orcid.org/0000-0002-3692-3099;
Email: a.armstrong@imperial.ac.uk

Authors

Edward L. Briggs – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Charlotte M. Zammit – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Alexander McDermott – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Stephanie Greed – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Dominic P. Affron – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Charlotte Leinfellner – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Hannah R. Cudmore – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Ruth R. Tweedy – Molecular Sciences Research Hub,
Department of Chemistry, Imperial College London, London
W12 0BZ, U.K.

Renzo Luisi – Department of Pharmacy—Drug Sciences,
University of Bari, Bari 70125, Italy; orcid.org/0000-0002-9882-7908

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acs.joc.1c00373>

Author Contributions

All authors have given approval to the final version of the manuscript.

Funding

We gratefully acknowledge EPSRC for funding (studentships to E.L.B. and S.G. and doctoral prize fellowship to G.B.C.) and The Royal Society [University Research Fellowship (UF140161, to J.A.B.) and Research Grants (RG150444 and RGF\EA\180031)]. This work was additionally supported by grants from the Institute of Chemical Biology (Imperial College London) and EPSRC (Studentship award EP/F500416/1). The circular dichroism facility at the University of Leeds was funded by the Wellcome Trust (094232).

Notes

The authors declare no competing financial interest.
A version of this manuscript was deposited on the preprint repository ChemRxiv.⁶⁴

ACKNOWLEDGMENTS

The authors thank Reach Separations (BioCity NG1 1GF, U.K.) for supporting this work by conducting preparatory and analytical chiral HPLC of compounds **10g**, **19f**, and **19g**. The authors are grateful to Prof. Henry Rzepa (Imperial College)

for invaluable advice and discussions on CD spectra calculations.

REFERENCES

- (1) (a) Lücking, U. Sulfoximines: A Neglected Opportunity in Medicinal Chemistry. *Angew. Chem., Int. Ed.* **2013**, *52*, 9399–9408. (b) Lücking, U. Neglected Sulfur(vi) Pharmacophores in Drug Discovery: Exploration of Novel Chemical Space by the Interplay of Drug Design and Method Development. *Org. Chem. Front.* **2019**, *6*, 1319–1324.
- (2) Chinthakindi, P. K.; Naicker, T.; Thota, N.; Govender, T.; Kruger, H. G.; Arvidsson, P. I. Sulfonimidamides in Medicinal and Agricultural Chemistry. *Angew. Chem., Int. Ed.* **2017**, *56*, 4100–4109.
- (3) Rowe, W. B.; Meister, A. Identification of L-Methionine-S-Sulfoximine as the Convulsant Isomer of Methionine Sulfoximine. *Proc. Natl. Acad. Sci. U.S.A.* **1970**, *66*, 500–506.
- (4) (a) Sirvent, J. A.; Lücking, U. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates. *ChemMedChem* **2017**, *12*, 487–501. (b) Frings, M.; Bolm, C.; Blum, A.; Gnam, C. Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in Vitro Parameters Relevant for Drug Discovery. *Eur. J. Med. Chem.* **2017**, *126*, 225–245. (c) Wiezorek, S.; Lamers, P.; Bolm, C. Conversion and Degradation Pathways of Sulfoximines. *Chem. Soc. Rev.* **2019**, *48*, 5408–5423. (d) Mäder, P.; Kattner, L. Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry. *J. Med. Chem.* **2020**, *63*, 14243–14275.
- (5) (a) Lücking, U.; Jautelat, R.; Krüger, M.; Brumby, T.; Lienau, P.; Schäfer, M.; Briem, H.; Schulze, J.; Hillisch, A.; Reichel, A.; et al. The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-[[4-[[[(1R,2R)-2-Hydroxy-1-Methylpropyl]Oxy]-5-(Trifluoromethyl)Pyrimidin-2-Yl]Amino]phenyl]Sulfoximide (BAY 1000394) for the Treatment of Cancer. *ChemMedChem* **2013**, *8*, 1067–1085. (b) Foote, K. M.; Nissink, J. W. M.; McGuire, T.; Turner, P.; Guichard, S.; Yates, J. W. T.; Lau, A.; Blades, K.; Heathcote, D.; Odedra, R.; et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. *J. Med. Chem.* **2018**, *61*, 9889–9907. (c) Lücking, U.; Scholz, A.; Lienau, P.; Siemeister, G.; Kosemund, D.; Bohlmann, R.; Briem, H.; Terebesi, I.; Meyer, K.; Prella, K.; Denner, K.; Bömer, U.; Schäfer, M.; Eis, K.; Valencia, R.; Ince, S.; von Nussbaum, F.; Mumberg, D.; Ziegelbauer, K.; Klebl, B.; Choidas, A.; Nussbaumer, P.; Baumann, M.; Schultz-Fademrecht, C.; Rühler, G.; Eickhoff, J.; Brands, M. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. *ChemMedChem* **2017**, *12*, 1776–1793.
- (6) (a) Palmer, J. T.; Rasnick, D.; Klaus, J. L.; Bromme, D. Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors. *J. Med. Chem.* **1995**, *38*, 3193–3196. (b) Roush, W. R.; Gwaltney, S. L.; Cheng, J.; Scheidt, K. A.; McKerrow, J. H.; Hansell, E. Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases. *J. Am. Chem. Soc.* **1998**, *120*, 10994–10995. (c) Kerr, I. D.; Lee, J. H.; Farady, C. J.; Marion, R.; Rickert, M.; Sajid, M.; Pandey, K. C.; Caffrey, C. R.; Legac, J.; Hansell, E.; McKerrow, J. H.; Craik, C. S.; Rosenthal, P. J.; Brinen, L. S. Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design. *J. Biol. Chem.* **2009**, *284*, 25697–25703. (d) Pakavathkumar, P.; Noël, A.; Lecrux, C.; Tubeleviciute-Aydin, A.; Hamel, E.; Ahlfors, J.-E.; LeBlanc, A. C. Caspase Vinyl Sulfone Small Molecule Inhibitors Prevent Axonal Degeneration in Human Neurons and Reverse Cognitive Impairment in Caspase-6-Overexpressing Mice. *Mol. Neurodegener.* **2017**, *12*, No. 22.
- (7) Jacobsen, W.; Christians, U.; Benet, L. Z. In Vitro Evaluation of the Disposition of a Novel Cysteine Protease Inhibitor. *Drug Metab. Dispos.* **2000**, *28*, 1343–1351.

- (8) Anscombe, E.; Meschini, E.; Mora-Vidal, R.; Martin, M. P.; Staunton, D.; Geitmann, M.; Danielson, U. H.; Stanley, W. A.; Wang, L. Z.; Reuillon, T.; Golding, B. T.; Cano, C.; Newell, D. R.; Noble, M. E. M.; Wedge, S. R.; Endicott, J. A.; Griffin, R. J. Identification and Characterization of an Irreversible Inhibitor of CDK2. *Chem. Biol.* **2015**, *22*, 1159–1164.
- (9) Ward, R. A.; Colclough, N.; Challinor, M.; Debreczeni, J. E.; Eckersley, K.; Fairley, G.; Feron, L.; Flemington, V.; Graham, M. A.; Greenwood, R.; Hopcroft, P.; Howard, T. D.; James, M.; Jones, C. D.; Jones, C. R.; Renshaw, J.; Roberts, K.; Snow, L.; Tonge, M.; Yeung, K. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. *J. Med. Chem.* **2015**, *58*, 4790–4801.
- (10) Ostrem, J. M.; Peters, U.; Sos, M. L.; Wells, J. A.; Shokat, K. M. K-Ras(G12C) Inhibitors Allosterically Control GTP Affinity and Effector Interactions. *Nature* **2013**, *503*, 548–551.
- (11) Li, X.; Zuo, Y.; Tang, G.; Wang, Y.; Zhou, Y.; Wang, X.; Guo, T.; Xia, M.; Ding, N.; Pan, Z. Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton's Tyrosine Kinase with in Vivo Antitumor Activity. *J. Med. Chem.* **2014**, *57*, 5112–5128.
- (12) Turnbull, A. P.; Ioannidis, S.; Krajewski, W. W.; Pinto-Fernandez, A.; Heride, C.; Martin, A. C. L.; Tonkin, L. M.; Townsend, E. C.; Buker, S. M.; Lancia, D. R.; Caravella, J. A.; Toms, A. V.; Charlton, T. M.; Lahdenranta, J.; Wilker, E.; Follows, B. C.; Evans, N. J.; Stead, L.; Alli, C.; Zarayskiy, V. V.; Talbot, A. C.; Buckmelter, A. J.; Wang, M.; McKinnon, C. L.; Saab, F.; McGouran, J. F.; Century, H.; Gersch, M.; Pittman, M. S.; Marshall, C. G.; Raynham, T. M.; Simcox, M.; Stewart, L. M. D.; McLoughlin, S. B.; Escobedo, J. A.; Bair, K. W.; Dinsmore, C. J.; Hammonds, T. R.; Kim, S.; Urbé, S.; Clague, M. J.; Kessler, B. M.; Komander, D. Molecular Basis of USP7 Inhibition by Selective Small-Molecule Inhibitors. *Nature* **2017**, *550*, 481–486.
- (13) (a) Fang, Y.; Luo, Z.; Xu, X. Recent Advances in the Synthesis of Vinyl Sulfones. *RSC Adv.* **2016**, *6*, 59661–59676. (b) Reuter, D. C.; McIntosh, J. E.; Guinn, A. C.; Madera, A. M. Synthesis of Vinyl Sulfonamides Using the Horner Reaction. *Synthesis* **2003**, 2321–2324. (c) Roush, W. R.; Cheng, J.; Knapp-Reed, B.; Alvarez-Hernandez, A.; McKerrow, J. H.; Hansell, E.; Engel, J. C. Potent Second Generation Vinyl Sulfonamide Inhibitors of the Trypanosomal Cysteine Protease Cruzain. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 2759–2762. (d) Craven, G. B.; Affron, D. P.; Raymond, P. N.; Mann, D. J.; Armstrong, A. Vinyl Sulfonamide Synthesis for Irreversible Tethering via a Novel α -Selenoether Protection Strategy. *MedChemComm* **2019**, *10*, 158–163. (e) Kiemele, E. R.; Wathier, M.; Bichler, P.; Love, J. A. Total Synthesis of K777: Successful Application of Transition-Metal-Catalyzed Alkyne Hydrothiolation toward the Modular Synthesis of a Potent Cysteine Protease Inhibitor. *Org. Lett.* **2016**, *18*, 492–495.
- (14) (a) Jones, L. H. Reactive Chemical Probes: Beyond the Kinase Cysteine. *Angew. Chem., Int. Ed.* **2018**, *57*, 9220–9223. (b) Gehringer, M.; Laufer, S. A. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. *J. Med. Chem.* **2019**, *62*, 5673–5724. (c) Sutanto, F.; Konstantinidou, M.; Dömling, A. Covalent Inhibitors: A Rational Approach to Drug Discovery. *RSC Med. Chem.* **2020**, *11*, 876–884.
- (15) Cisar, J. S.; Cravatt, B. F. Fully Functionalized Small-Molecule Probes for Integrated Phenotypic Screening and Target Identification. *J. Am. Chem. Soc.* **2012**, *134*, 10385–10388.
- (16) Wang, Y.; Dix, M. M.; Bianco, G.; Remsburg, J. R.; Lee, H.-Y.; Kalocsay, M.; Gygi, S. P.; Forli, S.; Vite, G.; Lawrence, R. M.; Parker, C. G.; Cravatt, B. F. Expedited Mapping of the Ligandable Proteome Using Fully Functionalized Enantiomeric Probe Pairs. *Nat. Chem.* **2019**, *11*, 1113–1123.
- (17) (a) Nonoo, R. H.; Armstrong, A.; Mann, D. J. Kinetic Template-Guided Tethering of Fragments. *ChemMedChem* **2012**, *7*, 2082–2086. (b) Kathman, S. G.; Xu, Z.; Statsyuk, A. V. A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases. *J. Med. Chem.* **2014**, *57*, 4969–4974. (c) Craven, G. B.; Affron, D. P.; Allen, C. E.; Matthies, S.; Greener, J. G.; Morgan, R. M. L.; Tate, E. W.; Armstrong, A.; Mann, D. J. High-Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery. *Angew. Chem., Int. Ed.* **2018**, *57*, 5257–5261. (d) Resnick, E.; Bradley, A.; Gan, J.; Douangamath, A.; Krojer, T.; Sethi, R.; Geurink, P. P.; Aimon, A.; Amitai, G.; Bellini, D.; Bennett, J.; Fairhead, M.; Fedorov, O.; Gabizon, R.; Gan, J.; Guo, J.; Plotnikov, A.; Reznik, N.; Ruda, G. F.; Diaz-Sáez, L.; Straub, V. M.; Szommer, T.; Velupillai, S.; Zaidman, D.; Zhang, Y.; Coker, A. R.; Dowson, C. G.; Barr, H. M.; Wang, C.; Huber, K. V. M.; Brennan, P. E.; Ovaia, H.; von Delft, F.; London, N. Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening. *J. Am. Chem. Soc.* **2019**, *141*, 8951–8968. (e) Douangamath, A.; Fearon, D.; Gehrtz, P.; Krojer, T.; Lukačič, P.; Owen, C. D.; Resnick, E.; Strain-Damerell, C.; Aimon, A.; Ábrányi-Balogh, P.; Brandão-Neto, J.; Carbery, A.; Davison, G.; Dias, A.; Downes, T. D.; Dunnett, L.; Fairhead, M.; Firth, J. D.; Jones, S. P.; Keeley, A.; Keserü, G. M.; Klein, H. F.; Martin, M. P.; Noble, M. E. M.; O'Brien, P.; Powell, A.; Reddi, R. N.; Skyner, R.; Snee, M.; Waring, M. J.; Wild, C.; London, N.; von Delft, F.; Walsh, M. A. Crystallographic and Electrophilic Fragment Screening of the SARS-CoV-2 Main Protease. *Nat. Commun.* **2020**, *11*, No. 5047. (f) Craven, G. B.; Affron, D. P.; Kösel, T.; Wong, T. L. M.; Jukes, Z. H.; Liu, C.-T.; Morgan, R. M. L.; Armstrong, A.; Mann, D. J. Multiparameter Kinetic Analysis for Covalent Fragment Optimization Using Quantitative Irreversible Tethering (QIT). *ChemBioChem* **2020**, *21*, 3417–3422.
- (18) Keeley, A.; Petri, L.; Ábrányi-Balogh, P.; Keserü, G. M. Covalent Fragment Libraries in Drug Discovery. *Drug Discovery Today* **2020**, *25*, 983–996.
- (19) (a) Hwang, K.-J.; Logusch, E. W. A Convenient Synthesis of Vinyl Sulfoximines from β -Hydroxyalkyl Sulfoximines. *Tetrahedron Lett.* **1987**, *28*, 4149–4152. (b) Craig, D.; Geach, N. J. Synthesis of E-N-Unfunctionalized α,β -Unsaturated Sulfoximines and N-Trifluoromethanesulfonyl Derivatives. *Synlett* **1993**, 1993, 481–482.
- (20) Erdelmeier, I.; Gais, H.-J. Stereoselective Synthesis of Enantiomerically Pure 1-(E)-Alkenylsulfoximines. *Tetrahedron Lett.* **1985**, *26*, 4359–4362.
- (21) (a) Hwang, K. J. A Convenient Synthesis of Free Vinyl Sulfoximines from Methyl Sulfoximines. *Bull. Korean Chem. Soc.* **2000**, *21*, 125–127. (b) McGrath, M. J.; Bolm, C. The Use of Chiral Lithium Amides in the Desymmetrisation of N-Trialkylsilyl Dimethyl Sulfoximines. *Beilstein J. Org. Chem.* **2007**, *3*, No. 33. (c) Kahraman, M.; Sinishtaj, S.; Dolan, P. M.; Kensler, T. W.; Peleg, S.; Saha, U.; Chuang, S. S.; Bernstein, G.; Korczak, B.; Posner, G. H. Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone $1\alpha,25$ -Dihydroxyvitamin D 3. *J. Med. Chem.* **2004**, *47*, 6854–6863. (d) Gao, X.; Gaddam, V.; Altenhofer, E.; Tata, R. R.; Cai, Z.; Yongpruksa, N.; Garimallaprabhakaran, A. K.; Harmata, M. C-H Activation in S-Alkenyl Sulfoximines: An Endo 1,5-Hydrogen Migration. *Angew. Chem., Int. Ed.* **2012**, *51*, 7016–7019.
- (22) Chinthakindi, P. K.; Nandi, G. C.; Govender, T.; Kruger, H. G.; Naicker, T.; Arvidsson, P. I. An Efficient Protecting-Group-Free Synthesis of Vinyl Sulfoximines via Horner-Wadsworth-Emmons Reaction. *Synlett* **2016**, *27*, 1423–1427.
- (23) Carlström, K. E.; Chinthakindi, P. K.; Espinosa, B.; Al Nimer, F.; Arnér, E. S. J.; Arvidsson, P. I.; Piehl, F.; Johansson, K. Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate. *Neurotherapeutics* **2020**, *17*, 1142–1152.
- (24) Bräse, S.; Mende, M.; Jobelius, H. H.; Scharf, H.-D. Hydrazoic Acid and Azides. *Ullmann's Encyclopedia of Industrial Chemistry*; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2015; pp 1–11.
- (25) Mendiola, J.; Rincón, J. A.; Mateos, C.; Soriano, J. F.; de Frutos, O.; Niemeier, J. K.; Davis, E. M. Preparation, Use, and Safety of O-Mesitylenesulfonylhydroxylamine. *Org. Process Res. Dev.* **2009**, *13*, 263–267.
- (26) Davies, T. Q.; Tilby, M. J.; Ren, J.; Parker, N. A.; Skolc, D.; Hall, A.; Duarte, F.; Willis, M. C. Harnessing Sulfinyl Nitrenes: A

Unified One-Pot Synthesis of Sulfoximines and Sulfonimidamides. *J. Am. Chem. Soc.* **2020**, *142*, 15445–15453.

(27) For reviews, see: (a) Bizet, V.; Hendriks, C. M. M.; Bolm, C. Sulfur Imidations: Access to Sulfoximines and Sulfoximines. *Chem. Soc. Rev.* **2015**, *44*, 3378–3390. (b) Bull, J. A.; Degennaro, L.; Luisi, R. Straightforward Strategies for the Preparation of NH-Sulfoximines: A Serendipitous Story. *Synlett* **2017**, *28*, 2525–2538. (c) Nandi, G. C.; Arvidsson, P. I. Sulfonimidamides: Synthesis and Applications in Preparative Organic Chemistry. *Adv. Synth. Catal.* **2018**, *360*, 2976–3001. (d) Wojaczyńska, E.; Wojaczyński, J. Modern Stereoselective Synthesis of Chiral Sulfinyl Compounds. *Chem. Rev.* **2020**, *120*, 4578–4611.

(28) For selected leading methods for sulfoximine synthesis, see: (a) Okamura, H.; Bolm, C. Rhodium-Catalyzed Imination of Sulfoxides and Sulfides: Efficient Preparation of N-Unsubstituted Sulfoximines and Sulfoximines. *Org. Lett.* **2004**, *6*, 1305–1307. (b) Lai, C.; Mathieu, G.; Gabrielli Tabarez, L. P.; Lebel, H. Batch and Continuous-Flow Iron(II)-Catalyzed Synthesis of Sulfoximines and Sulfoximines Using N-Mesyloxycarbamates. *Chem. - Eur. J.* **2019**, *25*, 9423–9426. (c) Zenzola, M.; Doran, R.; Luisi, R.; Bull, J. A. Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides. *J. Org. Chem.* **2015**, *80*, 6391–6399. (d) Mendonça Matos, P.; Lewis, W.; Argent, S. P.; Moore, J. C.; Stockman, R. A. General Method for the Asymmetric Synthesis of N-H Sulfoximines via C–S Bond Formation. *Org. Lett.* **2020**, *22*, 2776–2780. (e) Aota, Y.; Kano, T.; Maruoka, K. Asymmetric Synthesis of Chiral Sulfoximines via the S-Arylation of Sulfinamides. *J. Am. Chem. Soc.* **2019**, *141*, 19263–19268. Also see refs 30 and 31.

(29) For selected leading methods for sulfonimidamide synthesis, see: (a) Yu, H.; Li, Z.; Bolm, C. Copper-Catalyzed Trans-sulfonamidation of Sulfinamides as a Key Step in the Preparation of Sulfonamides and Sulfonimidamides. *Angew. Chem., Int. Ed.* **2018**, *57*, 15602–15605. (b) Gao, B.; Li, S.; Wu, P.; Moses, J. E.; Sharpless, K. B. SuFEx Chemistry of Thionyl Tetrafluoride (SO₂F₄) with Organolithium Nucleophiles: Synthesis of Sulfonimidoyl Fluorides, Sulfoximines, Sulfonimidamides, and Sulfonimidates. *Angew. Chem., Int. Ed.* **2018**, *57*, 1939–1943. (c) Zasukha, S. V.; Timoshenko, V. M.; Tolmachev, A. A.; Pivnytska, V. O.; Gavrylenko, O.; Zherish, S.; Shermolovich, Y.; Grygorenko, O. O. Sulfonimidamides and Imidosulfuric Diamides: Compounds from an Underexplored Part of Biologically Relevant Chemical Space. *Chem. - Eur. J.* **2019**, *25*, 6928–6940. (d) Bremerich, M.; Conrads, C. M.; Langlet, T.; Bolm, C. Additions to N-Sulfinylamines as an Approach for the Metal-Free Synthesis of Sulfonimidamides: O-Benzotriazolyl Sulfonimidates as Activated Intermediates. *Angew. Chem., Int. Ed.* **2019**, *58*, 19014–19020. (e) Davies, T. Q.; Hall, A.; Willis, M. C. One-Pot, Three-Component Sulfonimidamide Synthesis Exploiting the Sulfinylamine Reagent N-Sulfinyltritylamine, TrNSO. *Angew. Chem., Int. Ed.* **2017**, *56*, 14937–14941. (f) Greed, S.; Briggs, E. L.; Idiris, F. I. M.; White, A. J. P.; Lücking, U.; Bull, J. A. Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur–Fluorine Exchange (SuFEx) Reaction. *Chem. - Eur. J.* **2020**, *26*, 12533–12538. Also See refs 32 and 33.

(30) Zenzola, M.; Doran, R.; Degennaro, L.; Luisi, R.; Bull, J. A. Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides. *Angew. Chem., Int. Ed.* **2016**, *55*, 7203–7207.

(31) (a) Tota, A.; Zenzola, M.; Chawner, S. J.; John-Campbell, S. S.; Carlucci, C.; Romanazzi, G.; Degennaro, L.; Bull, J. A.; Luisi, R. Synthesis of NH-Sulfoximines from Sulfides by Chemoselective One-Pot N- and O-Transfers. *Chem. Commun.* **2017**, *53*, 348–351. (b) Degennaro, L.; Tota, A.; De Angelis, S.; Andresini, M.; Cardellicchio, C.; Capozzi, M. A.; Romanazzi, G.; Luisi, R. *Eur. J. Org. Chem.* **2017**, *2017*, 6486–6490. (c) Tota, A.; Carlucci, C.; Pisano, L.; Cutolo, G.; Clarkson, G. J.; Romanazzi, G.; Degennaro, L.; Bull, J. A.; Rollin, P.; Luisi, R. Synthesis of Glycosyl Sulfoximines by a Highly Chemo- and Stereoselective NH- and O-Transfer to Thioglycosides. *Org. Biomol. Chem.* **2020**, *18*, 3893–3897.

(32) Also see: (a) Lohier, J.-F.; Glachet, T.; Marzag, H.; Gaumont, A.-C.; Reboul, V. Mechanistic Investigation of the NH-Sulfoximation of Sulfide. Evidence for λ 6-Sulfanenitrile Intermediates. *Chem. Commun.* **2017**, *53*, 2064–2067. (b) Chaabouni, S.; Lohier, J.-F.; Barthelemy, A.-L.; Glachet, T.; Anselmi, E.; Dagousset, G.; Diter, P.; Pégot, B.; Magnier, E.; Reboul, V. One-Pot Synthesis of Aryl- and Alkyl S-Perfluoroalkylated NH-Sulfoximines from Sulfides. *Chem. - Eur. J.* **2018**, *24*, 17006–17010. (c) Xie, Y.; Zhou, B.; Zhou, S.; Zhou, S.; Wei, W.; Liu, J.; Zhan, Y.; Cheng, D.; Chen, M.; Li, Y.; et al. Sulfoximine-Promoted Fast O Transfer: One-Step Synthesis of Sulfoximine from Sulfide. *ChemistrySelect* **2017**, *2*, 1620–1624.

(33) Izzo, F.; Schäfer, M.; Stockman, R.; Lücking, U. A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides. *Chem. - Eur. J.* **2017**, *23*, 15189–15193.

(34) Briggs, E. L.; Tota, A.; Colella, M.; Degennaro, L.; Luisi, R.; Bull, J. A. Synthesis of Sulfonimidamides from Sulfenamides via an Alkoxy-Amino- λ 6-Sulfanenitrile Intermediate. *Angew. Chem., Int. Ed.* **2019**, *58*, 14303–14310.

(35) Worch, C.; Mayer, A. C.; Bolm, C. Synthesis and Use of Chiral Sulfoximines. *Organosulfur Chemistry in Asymmetric Synthesis*; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2008; pp 209–232.

(36) Han, J.; Soloshonok, V. A.; Klika, K. D.; Drabowicz, J.; Wzorek, A. Chiral Sulfoxides: Advances in Asymmetric Synthesis and Problems with the Accurate Determination of the Stereochemical Outcome. *Chem. Soc. Rev.* **2018**, *47*, 1307–1350.

(37) Kuniyasu, H.; Ogawa, A.; Sato, K.; Ryu, I.; Kambe, N.; Sonoda, N. The First Example of Transition-Metal-Catalyzed Addition of Aromatic Thiols to Acetylenes. *J. Am. Chem. Soc.* **1992**, *114*, 5902–5903.

(38) Cao, C.; Fraser, L. R.; Love, J. A. Rhodium-Catalyzed Alkyne Hydrothiolation with Aromatic and Aliphatic Thiols. *J. Am. Chem. Soc.* **2005**, *127*, 17614–17615.

(39) Ogawa, A.; Ikeda, T.; Kimura, K.; Hirao, T. Highly Regio- and Stereocontrolled Synthesis of Vinyl Sulfides via Transition-Metal-Catalyzed Hydrothiolation of Alkynes with Thiols. *J. Am. Chem. Soc.* **1999**, *121*, 5108–5114.

(40) Gerber, R.; Frech, C. M. Alkyne Hydrothiolation Catalyzed by a Dichlorobis(Aminophosphine) Complex of Palladium: Selective Formation of Cis-Configured Vinyl Thioethers. *Chem. - Eur. J.* **2012**, *18*, 8901–8905.

(41) Shuai, S.; Bichler, P.; Kang, B.; Buckley, H.; Love, J. A. Catalytic Alkyne Hydrothiolation with Alkanethiols Using Wilkinson's Catalyst. *Organometallics* **2007**, *26*, 5778–5781.

(42) (a) Kolb, H. C.; Sharpless, K. B. The Growing Impact of Click Chemistry on Drug Discovery. *Drug Discovery Today* **2003**, *8*, 1128–1137. (b) Thirumurugan, P.; Matosiuk, D.; Jozwiak, K. Click Chemistry for Drug Development and Diverse Chemical–Biology Applications. *Chem. Rev.* **2013**, *113*, 4905–4979. (c) Horisawa, K. Specific and Quantitative Labeling of Biomolecules Using Click Chemistry. *Front. Physiol.* **2014**, *5*, No. 457.

(43) (a) Wright, M. H.; Sieber, S. A. Chemical Proteomics Approaches for Identifying the Cellular Targets of Natural Products. *Nat. Prod. Rep.* **2016**, *33*, 681–708. (b) Van Kersavond, T.; Nguyen, M. T. N.; Verhelst, S. H. L. Synthesis and Application of Activity-Based Probes for Proteases. *Methods in Molecular Biology*; Humana Press Inc., 2017; Vol 1574, pp 255–266. (c) Pickens, C. J.; Johnson, S. N.; Pressnall, M. M.; Leon, M. A.; Berkland, C. J. Practical Considerations, Challenges, and Limitations of Bioconjugation via Azide–Alkyne Cycloaddition. *Bioconjugate Chem.* **2018**, *29*, 686–701.

(44) (a) Teng, F.; Sun, S.; Jiang, Y.; Yu, J.-T.; Cheng, J. Copper-Catalyzed Oxidative C(Sp³)–H/N–H Coupling of Sulfoximines and Amides with Simple Alkanes via a Radical Process. *Chem. Commun.* **2015**, *51*, 5902–5905. (b) Zhu, H.; Teng, F.; Pan, C.; Cheng, J.; Yu, J.-T. Radical N-Arylation/Alkylation of Sulfoximines. *Tetrahedron Lett.* **2016**, *57*, 2372–2374. (c) Bohnen, C.; Bolm, C. N-Trifluoromethylthiolated Sulfoximines. *Org. Lett.* **2015**, *17*, 3011–3013. (d) Teng, F.; Cheng, J.; Yu, J.-T. Copper-Catalyzed N-

- Methylation/Ethylation of Sulfoximines. *Org. Biomol. Chem.* **2015**, *13*, 9934–9937. (e) Kim, J.; Ok, J.; Kim, S.; Choi, W.; Lee, P. H. Mild Copper–TBAF-Catalyzed N-Arylation of Sulfoximines with Aryl Siloxanes. *Org. Lett.* **2014**, *16*, 4602–4605. (f) Aithagani, S. K.; Dara, S.; Munagala, G.; Aruri, H.; Yadav, M.; Sharma, S.; Vishwakarma, R. A.; Singh, P. P. Metal-Free Approach for the Synthesis of N-Aryl Sulfoximines via Aryne Intermediate. *Org. Lett.* **2015**, *17*, 5547–5549. (g) Zou, Y.; Xiao, J.; Peng, Z.; Dong, W.; An, D. Transition Metal-Free Aroylation of NH-Sulfoximines with Methyl Arenes. *Chem. Commun.* **2015**, *51*, 14889–14892. (h) Zhao, Z.; Wang, T.; Yuan, L.; Jia, X.; Zhao, J. Oxidative Acylation of Sulfoximines with Methylarenes as an Acyl Donor. *RSC Adv.* **2015**, *5*, 75386–75389. (i) Bala, B. D.; Sharma, N.; Sekar, G. Sulfoximinocarbonylation of Aryl Halides Using Heterogeneous Pd/C Catalyst. *RSC Adv.* **2016**, *6*, 97152–97159.
- (45) Izzo, F.; Schäfer, M.; Lienau, P.; Ganzer, U.; Stockman, R.; Lücking, U. Exploration of Novel Chemical Space: Synthesis and In Vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides. *Chem. - Eur. J.* **2018**, *24*, 9295–9304.
- (46) Mabasa, T. F.; Awe, B.; Laming, D.; Kinfe, H. H. Design, Synthesis and Antiplasmodial Evaluation of Sulfoximine-Triazole Hybrids as Potential Antimalarial Prototypes. *Med. Chem.* **2019**, *15*, 685–692.
- (47) (a) Gegenava, M.; Chankvetadze, L.; Farkas, T.; Chankvetadze, B. Enantioseparation of Selected Chiral Sulfoxides in High-Performance Liquid Chromatography with Polysaccharide-Based Chiral Selectors in Polar Organic Mobile Phases with Emphasis on Enantiomer Elution Order. *J. Sep. Sci.* **2014**, *37*, 1083–1088. (b) Sardella, R.; Ianni, F.; Di Michele, A.; Di Capua, A.; Carotti, A.; Anzini, M.; Natalini, B. Enantioresolution and Stereochemical Characterization of Two Chiral Sulfoxides Endowed with COX-2 Inhibitory Activity. *Chirality* **2017**, *29*, 536–540. (c) Ferretti, R.; Carradori, S.; Guglielmi, P.; Pierini, M.; Casulli, A.; Cirilli, R. Enantiomers of Triclabendazole Sulfoxide: Analytical and Semi-preparative HPLC Separation, Absolute Configuration Assignment, and Transformation into Sodium Salt. *J. Pharm. Biomed. Anal.* **2017**, *140*, 38–44.
- (48) (a) del Nozal, M. J.; Toribio, L.; Bernal, J. L.; Alonso, C.; Jiménez, J. J. Chiral Separation of Omeprazole and Several Related Benzimidazoles Using Supercritical Fluid Chromatography. *J. Sep. Sci.* **2004**, *27*, 1023–1029. (b) West, C.; Konjaria, M.-L.; Shashvashvili, N.; Lemasson, E.; Bonnet, P.; Kakava, R.; Volonterio, A.; Chankvetadze, B. Enantioseparation of Novel Chiral Sulfoxides on Chlorinated Polysaccharide Stationary Phases in Supercritical Fluid Chromatography. *J. Chromatogr. A* **2017**, *1499*, 174–182.
- (49) Parsons, S. Determination of Absolute Configuration Using X-Ray Diffraction. *Tetrahedron: Asymmetry* **2017**, *28*, 1304–1313.
- (50) Seco, J. M.; Quiñoá, E.; Riguera, R. The Assignment of Absolute Configuration by NMR. *Chem. Rev.* **2004**, *104*, 17–118.
- (51) Polavarapu, P. Determination of the Absolute Configurations of Chiral Drugs Using Chiroptical Spectroscopy. *Molecules* **2016**, *21*, No. 1056.
- (52) Berova, N.; Di Bari, L.; Pescitelli, G. Application of Electronic Circular Dichroism in Configurational and Conformational Analysis of Organic Compounds. *Chem. Soc. Rev.* **2007**, *36*, 914.
- (53) Xiong, F.; Yang, B.-B.; Zhang, J.; Li, L. Enantioseparation, Stereochemical Assignment and Chiral Recognition Mechanism of Sulfoxide-Containing Drugs. *Molecules* **2018**, *23*, No. 2680.
- (54) Worch, C.; Atodiresei, I.; Raabe, G.; Bolm, C. Synthesis of Enantiopure Sulfonimidamides and Elucidation of Their Absolute Configuration by Comparison of Measured and Calculated CD Spectra and X-ray Crystal Structure Determination. *Chem. - Eur. J.* **2010**, *16*, 677–683.
- (55) Bruhn, T.; Schaumlöffel, A.; Hemberger, Y.; Bringmann, G. SpecDis: Quantifying the Comparison of Calculated and Experimental Electronic Circular Dichroism Spectra. *Chirality* **2013**, *25*, 243–249.
- (56) Reach Separations specialise in chromatography for the analysis and purification of small molecules with extensive equipment and expertise: <https://reachseparations.com/>.
- (57) Wimmer, A.; König, B. N-Arylation of NH-Sulfoximines via Dual Nickel Photocatalysis. *Org. Lett.* **2019**, *21*, 2740–2744.
- (58) Bach, T.; Körber, C. The Preparation of N-Tert-Butyloxycarbonyl-(Boc)-Protected Sulfoximines and Sulfinimines by an Iron(II)-Mediated Nitrene Transfer from BocN₃ to Sulfoxides and Sulfides. *Eur. J. Org. Chem.* **1999**, *1999*, 1033–1039.
- (59) Dong, S.; Frings, M.; Cheng, H.; Wen, J.; Zhang, D.; Raabe, G.; Bolm, C. Organocatalytic Kinetic Resolution of Sulfoximines. *J. Am. Chem. Soc.* **2016**, *138*, 2166–2169.
- (60) Kuniyasu, H.; Ogawa, A.; Sato, K.; Ryu, I.; Kambe, N.; Sonoda, N. The First Example of Transition-Metal-Catalyzed Addition of Aromatic Thiols to Acetylenes. *J. Am. Chem. Soc.* **1992**, *114*, 5902–5903.
- (61) Zheng, Y.; Du, X.; Bao, W. L-Proline Promoted Cross-Coupling of Vinyl Bromide with Thiols Catalyzed by CuBr in Ionic Liquid. *Tetrahedron Lett.* **2006**, *47*, 1217–1220.
- (62) Leca, D.; Song, K.; Amatore, M.; Fensterbank, L.; Lacôte, E.; Malacria, M. Iodine(III)-Mediated Preparations of Nitrogen-Containing Sulfur Derivatives: Dramatic Influence of the Sulfur Oxidation State. *Chem. - Eur. J.* **2004**, *10*, 906–916.
- (63) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. *Gaussian 16*, revision C.01, Gaussian, Inc.: Wallingford, CT, 2019.
- (64) Craven, G. B.; Briggs, E. L.; Zammit, C. M.; McDermott, A.; Greed, S.; Affron, D. P.; Leinfellner, C.; Cudmore, H. R.; Tweedy, R. R.; Luisi, R.; Bull, J. A.; Armstrong, A. Synthesis and Configurational Assignment of Vinyl Sulfoximines and Sulfonimidamides. *ChemRxiv* **2021**, DOI: 10.26434/CHEMRXIV.13947413.V1.